



Clinical trial results:

Efficacy, Safety, Tolerability and Pharmacokinetics of Tofacitinib for Treatment of Systemic Juvenile Idiopathic Arthritis (sJIA) With Active Systemic Features in Children and Adolescent Subjects

Summary

EudraCT number	2017-002018-29
Trial protocol	SK PL DE BE IT NL SE HU
Global end of trial date	27 March 2024

Results information

Result version number	v1 (current)
This version publication date	10 October 2024
First version publication date	10 October 2024

Trial information

Trial identification

Sponsor protocol code	A3921165
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03000439
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000576-PIP01-09
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 July 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	27 March 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the sustained efficacy of tofacitinib versus placebo in sJIA participants, as measured by time to sJIA flare in the double-blind randomized withdrawal phase.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 May 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 2
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Brazil: 3
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	China: 26
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	India: 22
Country: Number of subjects enrolled	Israel: 7
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Mexico: 4
Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	Russian Federation: 3
Country: Number of subjects enrolled	South Africa: 9
Country: Number of subjects enrolled	Spain: 4
Country: Number of subjects enrolled	Türkiye: 1
Country: Number of subjects enrolled	Ukraine: 7
Country: Number of subjects enrolled	United States: 6
Worldwide total number of subjects	100
EEA total number of subjects	8

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	60
Adolescents (12-17 years)	40
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Details participants who were diagnosed with Systemic Juvenile Idiopathic Arthritis (sJIA) with active systemic features were enrolled.

Pre-assignment

Screening details:

A total of 168 participants were screened, of which 68 failed screening and only 100 participants were enrolled in open label part 1 (OLP1). From the total of 100 participants enrolled into OLP1 of the study, 54 participants were treated in open label part 2 (OLP2), and 59 participants were randomised between the treatment groups in the DB phase.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Blinding implementation details:

OL Part 1 and Part 2 was open label and allocation was not applicable

Arms

Are arms mutually exclusive?	No
Arm title	Tofacitinib 5mg BID Open_Label (OL) Part 1

Arm description:

Participants were administered tofacitinib 5 milligram (mg) twice a day (BID) via the oral route and continued to receive a stable dose of corticosteroids (Cs) during open label part 1.

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution, Tablet
Routes of administration	Oral use

Dosage and administration details:

Tofacitinib 5 mg was administered as an oral tablet BID for participants greater than equal to ($\geq$) 40 kilograms (kg) and as an equivalent weight-based lower dose of tofacitinib oral solution (1 mg/mL) BID for participants less than ($<$) 40 kg.

Arm title	Tofacitinib 5mg BID OL Part 2
------------------	-------------------------------

Arm description:

Participants who achieved sJIA American college of rheumatology (ACR) 50 response and maintained sJIA ACR 30 response for 4 weeks were administered tofacitinib 5 mg BID and tapering dose of CSs for participants treated with 0.2 milligram/kilogram/day (mg/kg/day) oral prednisone (or equivalent).

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Tofacitinib 5 mg was administered as an oral tablet BID for participants $\geq$ 40 kg and as an equivalent weight-based lower dose of tofacitinib oral solution (1 mg/mL) BID for participants $<$ 40 kg.

Arm title	Tofacitinib 5mg BID Double-Blind (DB)
------------------	---------------------------------------

Arm description:

Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase continued to receive tofacitinib 5 mg BID orally during the double-blind withdrawal phase of the study.

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Tofacitinib 5 mg was administered as an oral tablet BID for participants ≥ 40 kg and as an equivalent weight-based lower dose of tofacitinib oral solution (1 mg/mL) BID for participants < 40 kg.

Arm title	Placebo DB
------------------	------------

Arm description:

Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase were randomised to receive placebo BID orally during the double-blind withdrawal phase of the study.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Placebo of tofacitinib 5 mg was administered as an oral tablet BID for participants ≥ 40 kg and as an equivalent weight-based lower dose of tofacitinib oral solution (1 mg/mL) BID for participants < 40 kg.

Number of subjects in period 1	Tofacitinib 5mg BID Open_Label (OL) Part 1	Tofacitinib 5mg BID OL Part 2	Tofacitinib 5mg BID Double-Blind (DB)
Started	100	54	28
Completed	76	37	14
Not completed	24	17	14
Adverse event, non-fatal	2	-	2
Adverse event, serious non-fatal	4	-	-
Unspecified	2	5	10
Withdrawal by parent/guardian	-	-	2
Insufficient clinical response	16	12	-

Number of subjects in period 1	Placebo DB
Started	31
Completed	17
Not completed	14
Adverse event, non-fatal	-
Adverse event, serious non-fatal	1
Unspecified	11

Withdrawal by parent/guardian	-
Insufficient clinical response	2

Baseline characteristics

Reporting groups

Reporting group title	Tofacitinib 5mg BID Open_Label (OL) Part 1
Reporting group description:	
Participants were administered tofacitinib 5 milligram (mg) twice a day (BID) via the oral route and continued to receive a stable dose of corticosteroids (Cs) during open label part 1.	
Reporting group title	Tofacitinib 5mg BID OL Part 2
Reporting group description:	
Participants who achieved sJIA American college of rheumatology (ACR) 50 response and maintained sJIA ACR 30 response for 4 weeks were administered tofacitinib 5 mg BID and tapering dose of CSs for participants treated with 0.2 milligram/kilogram/day (mg/kg/day) oral prednisone (or equivalent).	
Reporting group title	Tofacitinib 5mg BID Double-Blind (DB)
Reporting group description:	
Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase continued to receive tofacitinib 5 mg BID orally during the double-blind withdrawal phase of the study.	
Reporting group title	Placebo DB
Reporting group description:	
Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase were randomised to receive placebo BID orally during the double-blind withdrawal phase of the study.	

Reporting group values	Tofacitinib 5mg BID Open_Label (OL) Part 1	Tofacitinib 5mg BID OL Part 2	Tofacitinib 5mg BID Double-Blind (DB)
Number of subjects	100	54	28
Age Categorical			
A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.			
Units: Participants			
2 to < 6 Years	17	10	3
6 to < 12 Years	43	21	12
12 to < 18 Years	40	23	13
Age continuous			
Units: years			
arithmetic mean	9.97	9.85	10.36
standard deviation	± 4.11	± 4.33	± 4.34
Gender categorical			
A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.			
Units: Participants			
Male	56	33	16
Female	44	21	12
Ethnicity			
A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.			
Units: Subjects			

Hispanic or Latino	14	11	3
Not Hispanic or Latino	86	43	25
Race			
A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.			
Units: Subjects			
White	39	23	11
Black or African American	7	4	3
Asian	49	23	13
Other	5	4	1

Reporting group values	Placebo DB	Total	
Number of subjects	31	213	
Age Categorical			
A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.			
Units: Participants			
2 to < 6 Years	6	36	
6 to < 12 Years	11	87	
12 to < 18 Years	14	90	
Age continuous			
Units: years			
arithmetic mean	10.35		
standard deviation	± 4.55	-	
Gender categorical			
A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.			
Units: Participants			
Male	22	127	
Female	9	86	
Ethnicity			
A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.			
Units: Subjects			
Hispanic or Latino	4	32	
Not Hispanic or Latino	27	181	
Race			
A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.			
Units: Subjects			
White	13	86	
Black or African American	2	16	
Asian	14	99	
Other	2	12	

End points

End points reporting groups

Reporting group title	Tofacitinib 5mg BID Open_Label (OL) Part 1
Reporting group description: Participants were administered tofacitinib 5 milligram (mg) twice a day (BID) via the oral route and continued to receive a stable dose of corticosteroids (Cs) during open label part 1.	
Reporting group title	Tofacitinib 5mg BID OL Part 2
Reporting group description: Participants who achieved sJIA American college of rheumatology (ACR) 50 response and maintained sJIA ACR 30 response for 4 weeks were administered tofacitinib 5 mg BID and tapering dose of CSs for participants treated with 0.2 milligram/kilogram/day (mg/kg/day) oral prednisone (or equivalent).	
Reporting group title	Tofacitinib 5mg BID Double-Blind (DB)
Reporting group description: Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase continued to receive tofacitinib 5 mg BID orally during the double-blind withdrawal phase of the study.	
Reporting group title	Placebo DB
Reporting group description: Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase were randomised to receive placebo BID orally during the double-blind withdrawal phase of the study.	

Primary: Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase

End point title	Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase ^[1]
End point description: Time to the disease flare=the number of days from randomisation to flare in the DB phase and calculated as date of disease flare=date of randomization plus (+)1. sJIA Flare=as at least one of the following criteria:Recurrence of fever (>38 degree Celsius/100.4-degree Fahrenheit) on 2 or more consecutive days) was considered due to SJIA activity.Worsening of 30 percent (%) or more in three or more of the six variables included: Number of joints with active arthritis and limited range of motion, disease activity, Parent child evaluation of overall well-being,functional ability (Disability Index), erythrocyte sedimentation rate (ESR), of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomisation into the withdrawal phase. 95% Confidence Interval (CI) based on Brookmeyer and Crowley Method. Double-Blind Full Analysis Set was used. 99999 indicates data could not be calculated due to less number of participants with events.	
End point type	Primary
End point timeframe: From randomization to up to 248 weeks	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double-Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Days				
median (confidence interval 95%)	99999 (186.0 to 99999)	295.0 (99.0 to 99999)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB, Placebo DB
Statistical analysis description: Hazard ratio and 95% CI was based on Cox proportional hazards model with treatment group as covariate.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1171
Method	Unstratified log-rank test
Parameter estimate	Hazard ratio (HR)
Point estimate	0.633
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.296
upper limit	1.354

Secondary: Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase

End point title	Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase ^[2]
End point description: sJIA Flare was defined as at least one of the following criteria: recurrence of fever (>38° C/100.4° F) on 2 or more consecutive days) was considered due to sJIA activity. Worsening of 30% or more in three or more of the six variables: number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability (CHAQ Disability Index), ESR. of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomisation into the withdrawal phase. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase.	
End point type	Secondary
End point timeframe: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Probability of event				
number (not applicable)				
DB Week 4	7.1	6.5		
DB Week 8	14.3	22.6		
DB Week 12	21.4	32.3		
DB Week 16	25.0	38.7		
DB Week 20	32.1	45.4		
DB Week 24	32.1	45.4		
DB Week 28	35.9	45.4		
DB Week 32	35.9	49.9		
DB Week 36	40.5	49.9		
DB Week 40	40.5	49.9		
DB Week 44	40.5	55.5		
DB Week 48	40.5	55.5		
DB Week 52	40.5	55.5		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.2
upper limit	13.6

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-10.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.2
upper limit	11.6

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-13.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.2
upper limit	9.8

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-13.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.9
upper limit	11.5

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-13.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.9
upper limit	11.5

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.9
upper limit	11.3

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-9.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.5
upper limit	15.6

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41.8
upper limit	11.8

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 32

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-39.5
upper limit	11.5

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 36

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-9.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.5
upper limit	16.7

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-9.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.5
upper limit	16.7

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41.8
upper limit	11.8

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41.8
upper limit	11.8

Secondary: Percentage of Participants who Achieved Corticosteroid Dose of Less Than or Equal to ($\leq$) 0.2 mg/kg/day or 10 mg/day: at the End of Open-label Phase Part 2

End point title	Percentage of Participants who Achieved Corticosteroid Dose of Less Than or Equal to ($\leq$) 0.2 mg/kg/day or 10 mg/day: at the End of Open-label Phase Part 2 ^[3]
-----------------	--

End point description:

95% CI was based on normal approximation. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2.

End point type	Secondary
----------------	-----------

End point timeframe:

From end of OL Part 1 to up to 24 weeks in OL Part 2

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of participants				
number (confidence interval 95%)	59.26 (46.15 to 72.36)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2

End point title	Percentage of Participants who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2 ^[4]
-----------------	--

End point description:

A successfully tapered participant was considered as the one that completed part 2 of the OL by reaching their target corticosteroid dose and maintained an adapted JIA American College of Rheumatology (ACR) 30 response for four weeks on this dose. The target CS dose at the end of part 2 included ≤ 0.5 mg/kg/day up to a maximum dose of 15 mg/day oral prednisone (or equivalent) for CS ≥ 0.8 mg/kg/day oral prednisone; reduction to ≤ 0.3 mg/kg/day up to a maximum of 12 mg/day oral prednisone (or equivalent) for CS ≤ 0.8 mg/kg/day $\rightarrow \geq 0.5$ mg/kg/day oral prednisone (or equivalent) and ≤ 0.2 mg/kg/day up to a maximum dose of 10 mg/day oral prednisone (or equivalent) for CS < 0.5 mg/kg/day $\rightarrow$ CS ≤ 0.2 mg/kg/day oral prednisone (or equivalent). 95% CI was based on normal approximation. Open-label part 2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2.

End point type	Secondary
----------------	-----------

End point timeframe:

From end of OL Part 1 to up to 24 weeks in OL Part 2

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of participants				
number (confidence interval 95%)	70.37 (58.19 to 82.55)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Adapted JIA ACR 30/50/70/90/100 Response at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

End point title	Percentage of Participants with Adapted JIA ACR 30/50/70/90/100 Response at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase ^[5]
-----------------	--

End point description:

Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of $\geq 30,50,70,90,100\%$, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by $\geq 30\%$. Variables included: number of joints with active arthritis (any joint with swelling, or in absence of swelling, limitation of motion accompanied by either pain on motion or tenderness); number of joints with limited range of motion; physician global evaluation of disease activity on a visual analog scale (VAS) from 0=no disease activity to 100=very severe disease activity; Parent/ legal guardian/Child evaluation of overall well-being on VAS from 0=very well to 100 millimeter (mm)= very poor; functional ability (Disability Index) ESR. DBFAS set was used. Missing response was imputed as non-response.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Percentage of participants				
number (not applicable)				
ACR30:DB Week 4	82.14	93.55		
ACR30:DB Week 8	82.14	80.65		
ACR30:DB Week 12	71.43	70.97		
ACR30:DB Week 16	71.43	61.29		
ACR30:DB Week 20	67.86	51.61		
ACR30:DB Week 24	64.29	54.84		

ACR30:DB Week 28	60.71	51.61		
ACR30:DB Week 32	60.71	51.61		
ACR30:DB Week 36	60.71	51.61		
ACR30:DB Week 40	60.71	51.61		
ACR30:DB Week 44	60.71	51.61		
ACR30:DB Week 48	60.71	48.39		
ACR30:DB Week 52	60.71	48.39		
ACR50:DB Week 4	82.14	93.55		
ACR50:DB Week 8	82.14	77.42		
ACR50:DB Week 12	71.43	70.97		
ACR50:DB Week 16	71.43	58.06		
ACR50:DB Week 20	67.86	48.39		
ACR50:DB Week 24	64.29	54.84		
ACR50:DB Week 28	60.71	51.61		
ACR50:DB Week 32	60.71	51.61		
ACR50:DB Week 36	60.71	51.61		
ACR50:DB Week 40	60.71	51.61		
ACR50:DB Week 44	60.71	48.39		
ACR50:DB Week 48	60.71	48.39		
ACR50:DB Week 52	60.71	48.39		
ACR70:DB Week 4	57.14	70.97		
ACR70:DB Week 8	67.86	77.42		
ACR70:DB Week 12	64.29	64.52		
ACR70:DB Week 16	60.71	54.84		
ACR70:DB Week 20	64.29	45.16		
ACR70:DB Week 24	53.57	51.61		
ACR70:DB Week 28	57.14	41.94		
ACR70:DB Week 32	60.71	48.39		
ACR70:DB Week 36	60.71	51.61		
ACR70:DB Week 40	60.71	48.39		
ACR70:DB Week 44	60.71	48.39		
ACR70:DB Week 48	60.71	48.39		
ACR70:DB Week 52	60.71	48.39		
ACR90:DB Week 4	28.57	48.39		
ACR90:DB Week 8	21.43	38.71		
ACR90:DB Week 12	25.00	38.71		
ACR90:DB Week 16	25.00	29.03		
ACR90:DB Week 20	21.43	29.03		
ACR90:DB Week 24	21.43	25.81		
ACR90:DB Week 28	17.86	25.81		
ACR90:DB Week 32	14.29	29.03		
ACR90:DB Week 36	28.57	35.48		
ACR90:DB Week 40	28.57	32.26		
ACR90:DB Week 44	28.57	29.03		
ACR90:DB Week 48	28.57	29.03		
ACR90:DB Week 52	28.57	29.03		
ACR100:DB Week 4	14.29	35.48		
ACR100:DB Week 8	10.71	29.03		
ACR100:DB Week 12	14.29	25.81		
ACR100:DB Week 16	17.86	25.81		
ACR100:DB Week 20	14.29	12.90		
ACR100:DB Week 24	17.86	19.35		

ACR100:DB Week 28	14.29	22.58		
ACR100:DB Week 32	10.71	25.81		
ACR100:DB Week 36	14.29	25.81		
ACR100:DB Week 40	21.43	29.03		
ACR100:DB Week 44	21.43	25.81		
ACR100:DB Week 48	25.00	25.81		
ACR100:DB Week 52	25.00	25.81		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR30: DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-11.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.02
upper limit	5.21

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR30: DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.37
upper limit	21.36

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR30: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR30: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR30: DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR30: DB week 36	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR30: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR30: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

ACR30: DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.49
upper limit	34.39

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

ACR30: DB Week 20

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	16.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.43
upper limit	40.92

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

ACR30: DB Week 16

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	10.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.82
upper limit	34.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR30: DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.68
upper limit	23.6

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR50: DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR50: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.45

Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.49
upper limit	34.39

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	13.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.76
upper limit	37.48

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.68
upper limit	23.6

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	4.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.72
upper limit	25.17

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-11.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.02
upper limit	5.21

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 20	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	19.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.2
upper limit	44.14

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR50: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

ACR70: DB Week 4

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-13.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.14
upper limit	10.49

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

ACR70: DB Week 8

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-9.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.28
upper limit	13.15

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

ACR70: DB Week 12

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.7
upper limit	24.24

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR70: DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	5.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.31
upper limit	31.06

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR70: DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	19.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.81
upper limit	44.06

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR70: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	1.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.55
upper limit	27.47

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR70: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	15.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.05
upper limit	40.46

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR70: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR70: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR90: DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-19.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-44.09
upper limit	4.46

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR70: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR70: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR 70: DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR90: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-4.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.02
upper limit	17.26

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR90: DB Week 8	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-17.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40.19
upper limit	5.63

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR90: DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-13.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.19
upper limit	9.77

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR90: DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-4.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.67
upper limit	18.61

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

ACR90: DB Week 20

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-7.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.66
upper limit	14.45

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

ACR70: DB Week 40

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

ACR90: DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.6
upper limit	22.68

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR90: DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-3.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.16
upper limit	19.78

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR90: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-6.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.65
upper limit	16.83

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR90: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-14.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.32
upper limit	5.83

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR90: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-7.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.89
upper limit	12.99

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR90: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.6
upper limit	22.68

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR100: DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-7.95

Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.89
upper limit	12.99

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR100: DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-11.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.65
upper limit	8.61

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR100: DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-18.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.98
upper limit	1.34

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR100: DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-21.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-42.45
upper limit	0.05

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR90: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.6
upper limit	22.68

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR100: DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	1.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.15
upper limit	18.91

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR100: DB Week 24	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.36
upper limit	18.37

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR100: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.91
upper limit	11.32

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: ACR100: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-15.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.29
upper limit	4.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

ACR30: DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

ACR100: DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.04
upper limit	21.43

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

ACR100: DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-4.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.02
upper limit	17.26

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR100: DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-7.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.66
upper limit	14.45

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR100: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-11.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.65
upper limit	8.61

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
ACR100: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.04
upper limit	21.43

Secondary: Percentage of Participants with Adapted JIA American College of Rheumatology (ACR) 30/50/70/90/100 Response at Part 1 Day 7, Weeks 2, 4, 8, 12, and 16: Open-label Phase Part 1

End point title	Percentage of Participants with Adapted JIA American College of Rheumatology (ACR) 30/50/70/90/100 Response at Part 1 Day 7, Weeks 2, 4, 8, 12, and 16: Open-label Phase Part 1 ^[6]
-----------------	--

End point description:

Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of $\geq 30\%$, 50%, 70%, 90%, 100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by $\geq 30\%$. Variables included: number of joints with active arthritis (any joint with swelling, or in absence of swelling, limitation of motion accompanied by either pain on motion or tenderness); number of joints with limited range of motion; physician global evaluation of disease activity on VAS (0: no disease activity-100:very severe disease activity); parent/legal guardian/Child evaluation of overall well-being on VAS (0:very well-100 mm:very poor); functional ability (CHAQ Disability Index) ESR. OLPT1 set used. All participants reported as 'Number of subjects analysed' contributed data to table; but may not have evaluable data for every row. "n": participants evaluable for specified time points & used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, and 16

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of participants				
number (confidence interval 95%)				
ACR30: Part 1 Day 7; n=99	26.26 (17.59 to 34.93)			
ACR30:Part 1 Week 2; n=99	42.42 (32.69 to 52.16)			
ACR30:Part 1 Week 4; n=97	68.04 (58.76 to 77.32)			
ACR30:Part 1 Week 8; n=82	86.59 (79.21 to 93.96)			
ACR30:Part 1 Week 12; n=44	90.91 (82.41 to 99.40)			
ACR30:Part 1 Week 16; n=24	83.33 (68.42 to 98.24)			
ACR50:Part 1 Day 7; n=99	18.18 (10.58 to 25.78)			
ACR50:Part 1 Week 2; n=99	28.28 (19.41 to 37.15)			
ACR50:Part 1 Week 4; n=97	44.33 (34.44 to 54.22)			
ACR50:Part 1 Week 8; n=83	59.04 (48.46 to 69.62)			
ACR50:Part 1 Week 12; n=44	79.55 (67.63 to 91.46)			
ACR50:Part 1 Week 16; n=24	75.00 (57.68 to 92.32)			

ACR70:Part 1 Day 7; n=99	10.10 (4.16 to 16.04)			
ACR70:Part 1 Week 2; n=99	16.16 (8.91 to 23.41)			
ACR70:Part 1 Week 4; n=97	19.59 (11.69 to 27.49)			
ACR70:Part 1 Week 8; n=82	34.15 (23.88 to 44.41)			
ACR70:Part 1 Week 12; n=44	38.64 (24.25 to 53.02)			
ACR70:Part 1 Week 16; n=24	33.33 (14.47 to 52.19)			
ACR90:Part 1 Day 7; n=99	5.05 (0.74 to 9.36)			
ACR90:Part 1 Week 2; n=99	6.06 (1.36 to 10.76)			
ACR90:Part 1 Week 4; n=97	11.34 (5.03 to 17.65)			
ACR90:Part 1 Week 8; n=82	18.29 (9.92 to 26.66)			
ACR90:Part 1 Week 12; n=44	15.91 (5.10 to 26.72)			
ACR90:Part 1 Week 16; n=24	16.67 (1.76 to 31.58)			
ACR100:Part 1 Day 7; n=99	3.03 (0 to 6.41)			
ACR100:Part 1 Week 2; n=99	5.05 (0.74 to 9.36)			
ACR100:Part 1 Week 4; n=97	8.25 (2.77 to 13.72)			
ACR100:Part 1 Week 8; n=82	13.41 (6.04 to 20.79)			
ACR100:Part 1 Week 12; n=44	9.09 (0.60 to 17.59)			
ACR100:Part 1 Week 16; n=24	8.33 (0 to 19.39)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Adapted JIA ACR 30/50/70/90/100 Response at Part 2 Weeks 4, 8, 12, 16, 20 and 24: Open-label Phase Part 2

End point title	Percentage of Participants with Adapted JIA ACR 30/50/70/90/100 Response at Part 2 Weeks 4, 8, 12, 16, 20 and 24: Open-label Phase Part 2 ^[7]
-----------------	--

End point description:

Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of $\geq 30\%$, 50%, 70%, 90%, 100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by $\geq 30\%$. Variables included: number of joints with active arthritis (i.e. any joint with swelling, or in absence of swelling, limitation of motion accompanied by either pain on motion or tenderness); number of joints with limited range of motion; physician global evaluation of disease activity on a VAS from 0=no disease activity to 100=very severe disease activity; parent/ legal guardian/Child evaluation of overall well-being on VAS from 0= very well to 100 mm= very poor; functional ability (CHAQ disability Index) ESR. OLPT2 analysis set was used. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 2 Weeks 4, 8, 12, 16, 20 and 24

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of participants				
number (confidence interval 95%)				
ACR30:Part 2 Week 4; n=50	90.00 (81.68 to 98.32)			
ACR30:Part 2 Week 8;n=40	87.50 (77.25 to 97.75)			
ACR30:Part 2 Week 12; n=31	90.32 (79.91 to 100)			
ACR30:Part 2 week 16;n=23	86.96 (73.19 to 100)			
ACR30:Part 2 Week 20;n=13	100 (100 to 100)			
ACR30:Part 2 Week 24;n=3	100 (100 to 100)			
ACR50:Part 2 Week 4;n=50	86.00 (76.38 to 95.62)			
ACR50:Part 2 Week 8;n=40	77.50 (64.56 to 90.44)			
ACR50:Part 2 Week 12;n=31	80.65 (66.74 to 94.55)			
ACR50:Part 2 Week 16;n=23	73.91 (55.97 to 91.86)			
ACR50:Part 2 Week 20;n=13	92.31 (77.82 to 100)			
ACR50:Part 2 Week 24;n=3	100 (100 to 100)			
ACR70:Part 2 Week 4;n=50	68.00 (55.07 to 80.93)			
ACR70:Part 2 Week 8;n=40	67.50 (52.98 to 82.02)			
ACR70:Part 2 Week 12;n=31	70.97 (54.99 to 86.95)			
ACR70:Part 2 Week 16;n=23	73.91 (55.97 to 91.86)			
ACR70:Part 2 Week 20;-n-13	92.31 (77.82 to 100)			
ACR70:Part 2 Week 24;n=3	66.67 (13.32 to 100)			
ACR90:Part 2 Week 4;n=50	32.00 (19.07 to 44.93)			
ACR90:Part 2 Week 8;n=40	27.50 (13.66 to 41.34)			
ACR90:Part 2 Week 12;n=31	22.58 (7.86 to 37.30)			
ACR90:Part 2 Week 16;n=23	34.78 (15.32 to 54.25)			
ACR90:Part 2 Week 20;n=13	53.85 (26.75 to 80.95)			

ACR90:Part 2 Week 24;n=3	33.33 (0 to 86.68)			
ACR100:Part 2 Week 4;n=50	28.00 (15.55 to 40.45)			
ACR100:Part 2 Week 8;n=40	27.50 (13.66 to 41.34)			
ACR100:Part 2 Week 12;n=31	16.13 (3.18 to 29.08)			
ACR100:Part 2 Week 16;n=23	26.09 (8.14 to 44.03)			
ACR100:Part 2 Week 20;n=13	38.46 (12.01 to 64.91)			
ACR100:Part 2 Week 24;n=3	33.33 (0 to 86.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Fever Attributed to sJIA at Part 1 Days 3, 7 and 14: Open-label Phase Part 1

End point title	Percentage of Participants with Fever Attributed to sJIA at Part 1 Days 3, 7 and 14: Open-label Phase Part 1 ^[8]
-----------------	---

End point description:

Fever was defined as an oral temperature of 38 degree Celsius/100.4 degree Fahrenheit. 95% CI was based on normal approximation. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under 'Number of Subjects Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1 Days 3, 7 and 14

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 1 Day 3; n=96	3.13 (0 to 6.61)			
Part 1 Day 7; n=97	1.03 (0 to 3.04)			
Part 1 Day 14; n=97	4.12 (0.17 to 8.08)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With C-reactive protein (CRP) $\leq$ 10 mg/L at Baseline, Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Percentage of Participants With C-reactive protein (CRP) $\leq$ 10 mg/L at Baseline, Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[9]
-----------------	--

End point description:

Percentage of participants with CRP $\leq$ 10 milligrams per liter (mg/L) along with 95% CI based on normal approximation is reported in this endpoint. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to Day 1 of study treatment), Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of participants				
number (confidence interval 95%)				
Baseline; n=100	30.00 (21.02 to 38.98)			
Part 1 Day 3; n=95	32.63 (23.20 to 42.06)			
Part 1 Day 7; n=97	45.36 (35.45 to 55.27)			
Part 1 Week 2; n=97	49.48 (39.53 to 59.43)			
Part 1 Week 4; n=97	55.67 (45.78 to 65.56)			
Part 1 Week 8; n=80	60.00 (49.26 to 70.74)			
Part 1 Week 12; n=44	59.09 (44.56 to 73.62)			
Part 1 Week 16; n=24	41.67 (21.94 to 61.39)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With C-reactive protein (CRP) $\leq$ 10 mg/L at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Percentage of Participants With C-reactive protein (CRP) <= 10 mg/L at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[10]
-----------------	---

End point description:

Percentage of participants with CRP <= 10 mg/L along with 95% CI based on normal approximation is reported in this endpoint. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 2 Week 4; n=50	68.00 (55.07 to 80.93)			
Part 2 Week 8; n=40	62.50 (47.50 to 77.50)			
Part 2 Week 12; n=31	51.61 (34.02 to 69.21)			
Part 2 Week 16; n=22	54.55 (33.74 to 75.35)			
Part 2 Week 20; n=13	76.92 (54.02 to 99.83)			
Part 2 Week 24; n=3	33.33 (0 to 86.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Absence of Fever due to sJIA at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Percentage of Participants With Absence of Fever due to sJIA at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[11]
-----------------	--

End point description:

Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this endpoint. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, 16

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 1 Day 7; n=97	83.51 (76.12 to 90.89)			
Part 1 Week 2; n=97	82.47 (74.91 to 90.04)			
Part 1 Week 4; n=97	90.72 (84.95 to 96.50)			
Part 1 Week 8; n=83	96.39 (92.37 to 100)			
Part 1 Week 12; n=44	100 (100 to 100)			
Part 1 Week 16; n=24	95.83 (87.84 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Absence of Fever due to sJIA at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Percentage of Participants With Absence of Fever due to sJIA at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[12]
-----------------	--

End point description:

Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this endpoint. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 2 Weeks 4, 8, 12, 16, 20 and 24

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 2 Week 4; n=50	98.00 (94.12 to 100)			
Part 2 Week 8; n=39	92.31 (83.94 to 100)			
Part 2 Week 12; n=31	96.77 (90.55 to 100)			
Part 2 Week 16; n=22	90.91 (78.90 to 100)			
Part 2 Week 20; n=12	100 (100 to 100)			
Part 2 Week 24; n=3	100 (100 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Absence of Fever due to sJIA at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double Blind Phase

End point title	Percentage of Participants With Absence of Fever due to sJIA at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double Blind Phase ^[13]
-----------------	--

End point description:

Percentage of participants with absence of fever due sJIA is reported in this endpoint. DBFAS consisted of all randomized participants who received at least one dose of investigational product in the double-blind phase. Missing response was imputed as non-response.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Percentage of participants				
number (not applicable)				
DB Week 4	85.71	93.55		
DB Week 8	85.71	80.65		
DB Week 12	75.00	74.19		
DB Week 16	71.43	61.29		
DB Week 20	67.86	51.61		
DB Week 24	64.29	54.84		

DB Week 28	60.71	51.61		
DB Week 32	60.71	51.61		
DB Week 36	60.71	51.61		
DB Week 40	60.71	51.61		
DB Week 44	60.71	51.61		
DB Week 48	60.71	48.39		
DB Week 52	60.71	48.39		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-7.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.42
upper limit	7.75

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.43
upper limit	23.04

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	10.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.82
upper limit	34.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	16.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.43
upper limit	40.92

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.49
upper limit	34.39

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 40

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	12.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.91
upper limit	37.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	5.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.94
upper limit	24.08

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.13
upper limit	34.33

Secondary: Change From Open Label Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) Erythrocyte Sedimentation Rate (ESR) at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

End point title	Change From Open Label Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) Erythrocyte Sedimentation Rate (ESR) at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 ^[14]
-----------------	--

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here "n" = participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 1 Day 7: n=98	-5.64 (± 5.20)			
Part 1 Week 2: n=98	-8.57 (± 5.97)			
Part 1 Week 4: n=97	-11.95 (± 6.53)			
Part 1 Week 8: n=81	-15.09 (± 7.27)			
Part 1 Week 12: n=44	-15.77 (± 7.24)			
Part 1 Week 16: n=24	-14.08 (± 6.09)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 1

End point title	Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 1 ^[15]
-----------------	--

End point description:

Time to the first adapted JIA ACR 30 response was measured in number of days since Day 1 (day of adapted JIA ACR 30 response – Day 1 + 1) in the Open-Label Phase Part 1. Participants that did not achieve an adapted JIA ACR30 response (absence of fever due to sJIA (temperature ≤38° C/100.4° F) in the preceding 7 days along with an improvement of at least 30% from baseline (Day 1 of study drug before first tofacitinib administration) in at least 3 of the 6 JIA core components, with worsening of > =30 in no more than 1 of the remaining components), which in Part 1 (withdrew from the study) were censored at their last available response assessment in Part 1. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. 95% CI was based on the Brookmeyer and Crowley Method.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 up to 16 weeks

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Days				
median (confidence interval 95%)	27.0 (15.0 to 29.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in JADAS-27 ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-Label Baseline in JADAS-27 ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[16]
-----------------	---

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 2 Week 4; n=50	-17.05 (± 8.18)			
Part 2 Week 8; n=40	-17.13 (± 8.14)			
Part 2 Week 12; n=31	-18.17 (± 7.74)			
Part 2 Week 16; n=23	-18.89 (± 7.56)			
Part 2 Week 20; n=13	-21.14 (± 5.78)			
Part 2 Week 24; n=3	-22.17 (± 7.58)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in JADAS-27 CRP at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

End point title	Change From Open-Label Baseline in JADAS-27 CRP at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 ^[17]
-----------------	---

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here "n" = participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 1 Day 7; n=97	-6.25 (± 5.53)			
Part 1 Week 2; n=96	-8.55 (± 6.10)			
Part 1 Week 4; n=97	-11.88 (± 7.28)			
Part 1 Week 8; n=80	-15.07 (± 8.46)			
Part 1 Week 12; n=44	-15.19 (± 7.73)			
Part 1 Week 16; n=24	-13.10 (± 6.37)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in JADAS-27 CRP at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-Label Baseline in JADAS-27 CRP at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[18]
-----------------	---

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here "n" = participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 2 Week 4; n=50	-17.16 (± 8.87)			
Part 2 Week 8; n=40	-17.44 (± 8.03)			
Part 2 Week 12; n=31	-18.99 (± 7.67)			
Part 2 Week 16; n=22	-20.31 (± 6.41)			
Part 2 Week 20; n=13	-22.16 (± 7.05)			
Part 2 Week 24; n=3	-25.61 (± 9.82)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Double-Blind Baseline in JADAS-27 ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Double-Blind Baseline in JADAS-27 ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52:
-----------------	---

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
least squares mean (standard error)				
DB Week 4; (n=27,30)	1.07 (± 0.84)	1.08 (± 0.79)		
DB Week 8; (n=25,24)	1.75 (± 1.08)	0.81 (± 1.06)		
DB Week 12; (n=21,22)	1.47 (± 1.46)	1.71 (± 1.40)		
DB Week 16; (n=21,19)	0.43 (± 1.03)	1.29 (± 1.04)		
DB Week 20; (n=19,14)	-1.04 (± 0.65)	0.05 (± 0.69)		
DB Week 24; (n=18,14)	-0.49 (± 0.57)	-0.79 (± 0.60)		
DB Week 28; (n=17,12)	2.58 (± 2.05)	3.86 (± 2.25)		
DB Week 32; (n=13,10)	-0.21 (± 0.77)	-0.68 (± 0.83)		
DB Week 36; (n=13,10)	-1.52 (± 0.50)	-1.26 (± 0.54)		
DB Week 40; (n=11,9)	-0.23 (± 0.91)	-0.96 (± 0.96)		
DB Week 44; (n=10,9)	-1.67 (± 0.75)	-0.83 (± 0.79)		
DB Week 48; (n=8,5)	-2.29 (± 0.38)	-2.06 (± 0.60)		
DB Week 52; (n=6,4)	-2.41 (± 0.60)	-1.65 (± 1.07)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
----------------------------	---------------------------------------

Statistical analysis description:

DB Week 16

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
-------------------	--

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.99
upper limit	2.28

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.54
upper limit	4.06

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.25
upper limit	4.12

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	2.38

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.86
upper limit	1.35

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.18
upper limit	3.63

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.22
upper limit	1.56

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.76
upper limit	1.3

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 32

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.98
upper limit	2.93

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.43
upper limit	1.93

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.46
upper limit	2.06

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.12
upper limit	0.94

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.85
upper limit	5.29

Secondary: Change From Double-Blind Baseline in JADAS-27 CRP at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Double-Blind Baseline in JADAS-27 CRP at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[20]
-----------------	---

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double-Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
least squares mean (standard error)				
DB Week 4; (n=26,31)	1.62 (± 0.96)	0.71 (± 0.90)		
DB Week 8; (n=25,25)	2.12 (± 0.95)	0.01 (± 0.93)		

DB Week 12; (n=21,22)	1.78 (± 1.46)	1.80 (± 1.40)		
DB Week 16; (n=21,19)	0.84 (± 1.09)	1.95 (± 1.08)		
DB Week 20; (n=19,15)	-0.17 (± 0.84)	0.36 (± 0.87)		
DB Week 24; (n=18,15)	1.58 (± 1.04)	-0.26 (± 1.08)		
DB Week 28; (n=17,12)	2.64 (± 1.86)	2.72 (± 2.04)		
DB Week 32; (n=12,9)	0.49 (± 0.99)	1.18 (± 1.07)		
DB Week 36; (n=13,10)	-1.59 (± 0.50)	-1.24 (± 0.53)		
DB Week 40; (n=11,9)	0.38 (± 1.15)	0.41 (± 1.21)		
DB Week 44; (n=10,9)	-1.09 (± 0.99)	1.50 (± 1.02)		
DB Week 48; (n=8,5)	-2.04 (± 0.51)	-1.23 (± 0.76)		
DB Week 52; (n=6,4)	-2.31 (± 0.60)	-1.85 (± 1.10)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	3.61

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	2.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.64
upper limit	4.86

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.25
upper limit	4.21

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.32
upper limit	2.09

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.04
upper limit	1.98

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	1.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.29
upper limit	4.97

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.89
upper limit	5.72

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.63
upper limit	3.58

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.89
upper limit	1.19

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.79
upper limit	2.41

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-2.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.67
upper limit	0.49

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.82
upper limit	1.19

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.27
upper limit	2.36

Secondary: Change From Open-Label Baseline in Number of Joints with Active Arthritis at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-Label Baseline in Number of Joints with
-----------------	--

End point description:

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Joints				
arithmetic mean (standard deviation)				
Part 2 Week 4; n=50	-7.78 (± 7.78)			
Part 2 Week 8; n=40	-7.73 (± 8.40)			
Part 2 Week 12; n=31	-9.26 (± 7.98)			
Part 2 Week 16; n=23	-10.00 (± 7.99)			
Part 2 Week 20; n=13	-10.85 (± 7.83)			
Part 2 Week 24; n=3	-13.67 (± 11.02)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in Number of Joints with Active Arthritis at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Change From Open-Label Baseline in Number of Joints with Active Arthritis at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[22]
-----------------	---

End point description:

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Joints				
arithmetic mean (standard deviation)				
Part 1 Day 7; n=99	-2.96 (± 4.17)			
Part 1 Week 2; n=99	-4.21 (± 5.31)			
Part 1 Week 4; n=97	-6.03 (± 6.04)			
Part 1 Week 8; n=83	-7.80 (± 9.25)			
Part 1 Week 12; n=44	-7.52 (± 7.38)			
Part 1 Week 16; n=24	-6.38 (± 7.87)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[23]
-----------------	--

End point description:

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Joints				
arithmetic mean (standard deviation)				

Part 1 Day 7; n=99	-1.83 (± 4.26)			
Part 1 Week 2; n=99	-2.06 (± 4.70)			
Part 1 Week 4; n=97	-2.90 (± 5.42)			
Part 1 Week 8; n=83	-4.36 (± 8.59)			
Part 1 Week 12; n=44	-3.64 (± 6.05)			
Part 1 Week 16; n=24	-2.33 (± 3.48)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[24]
-----------------	--

End point description:

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Joints				
arithmetic mean (standard deviation)				
Part 2 Week 4; n=50	-4.26 (± 6.75)			
Part 2 Week 8; n=40	-3.90 (± 6.08)			
Part 2 Week 12; n=31	-5.81 (± 7.48)			
Part 2 Week 16; n=23	-5.74 (± 7.13)			
Part 2 Week 20; n=13	-5.92 (± 9.32)			
Part 2 Week 24; n=3	-15.67 (± 11.02)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[25]
-----------------	--

End point description:

Physician global evaluation of disease activity was assessed on a VAS ranging from 0 to 10 mm, where 0=no activity and 10=maximum activity. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 1 Day 7; n=99	-1.18 (± 1.36)			
Part 1 Week 2; n=99	-1.82 (± 1.68)			
Part 1 Week 4; n=97	-2.62 (± 1.75)			
Part 1 Week 8; n=83	-3.40 (± 2.01)			
Part 1 Week 12; n=44	-3.66 (± 2.08)			
Part 1 Week 16; n=24	-3.50 (± 1.93)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[26]
-----------------	--

End point description:

Physician global evaluation of disease activity was assessed on a VAS ranging from 0 to 10 mm, where 0=no activity and 10=maximum activity. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 2 Week 4; n=50	-4.54 (± 2.10)			
Part 2 Week 8; n=40	-4.53 (± 1.74)			
Part 2 Week 12; n=31	-4.65 (± 1.57)			
Part 2 Week 16; n=23	-4.89 (± 1.77)			
Part 2 Week 20; n=13	-5.62 (± 1.21)			
Part 2 Week 24; n=3	-6.17 (± 1.44)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-Label Baseline in ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[27]
-----------------	--

End point description:

ESR was determined using an ESR testing kit. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Millimeter per hour				
arithmetic mean (standard deviation)				
Part 2 Week 4; n=50	-33.64 (± 28.16)			

Part 2 Week 8; n=40	-30.73 ($\pm$ 27.11)			
Part 2 Week 12; n=31	-27.52 ($\pm$ 28.13)			
Part 2 Week 16; n=23	-23.48 ($\pm$ 24.70)			
Part 2 Week 20; n=13	-37.54 ($\pm$ 20.93)			
Part 2 Week 24; n=3	-24.33 ($\pm$ 6.03)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in ESR at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Change From Open-Label Baseline in ESR at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[28]
-----------------	--

End point description:

ESR was determined using an ESR testing kit. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Millimeter per hour				
arithmetic mean (standard deviation)				
Part 1 Day 7; n=98	-11.00 ($\pm$ 16.96)			
Part 1 Week 2; n=99	-18.60 ($\pm$ 19.78)			
Part 1 Week 4; n=97	-24.70 ($\pm$ 23.86)			
Part 1 Week 8; n=81	-30.59 ($\pm$ 23.12)			
Part 1 Week 12; n=44	-31.74 ($\pm$ 21.75)			
Part 1 Week 16; n=24	-27.65 ($\pm$ 28.84)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in Child Health Assessment Questionnaire (CHAQ)- Parental Evaluation of Overall Well-being at Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Change From Open-Label Baseline in Child Health Assessment Questionnaire (CHAQ)- Parental Evaluation of Overall Well-being at Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[29]
-----------------	---

End point description:

The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle visual analog scale (VAS) where '0= Very Well and 10=Very Poorly. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Days 3,7, Part 1 Weeks 2, 4, 8, 12, 16

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 1 Day 3; n=96	-0.73 (± 1.53)			
Part 1 Day 7; n=99	-1.36 (± 1.91)			
Part 1 Week 2; n=98	-1.96 (± 1.89)			
Part 1 Week 4; n=97	-2.65 (± 2.44)			
Part 1 Week 8; n=83	-3.35 (± 2.38)			
Part 1 Week 12; n=44	-3.45 (± 2.45)			
Part 1 Week 16; n=24	-3.48 (± 2.78)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in CHAQ - Parental Evaluation of Overall Well-being at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-Label Baseline in CHAQ - Parental Evaluation of Overall Well-being at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[30]
-----------------	---

End point description:

The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0= Very Well and 10=Very Poorly. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 2 Week 4; n=50	-4.09 (± 2.68)			
Part 2 Week 8; n=40	-4.50 (± 2.88)			
Part 2 Week 12; n=31	-4.73 (± 2.83)			
Part 2 Week 16; n=23	-5.11 (± 2.50)			
Part 2 Week 20; n=13	-5.65 (± 2.89)			
Part 2 Week 24; n=3	-6.33 (± 2.31)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in CHAQ - Disability Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Change From Open-Label Baseline in CHAQ - Disability Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[31]
-----------------	--

End point description:

CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall Well-being. CHAQ disability index consisted of 30 items in 8 areas: 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to

3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid. OLP1 set was used. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here, "n":number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 1 Day 7; n=99	-0.21 (± 0.35)			
Part 1 Week 2; n=99	-0.38 (± 0.43)			
Part 1 Week 4; n=97	-0.52 (± 0.56)			
Part 1 Week 8; n=83	-0.59 (± 0.57)			
Part 1 Week 12; n=44	-0.51 (± 0.56)			
Part 1 Week 16; n=24	-0.74 (± 0.73)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in CHAQ - Disability Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-Label Baseline in CHAQ - Disability Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[32]
-----------------	--

End point description:

CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. CHAQ disability index consisted of 30 items in 8 areas, 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to-3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid. OLPT2 set was used. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here, "n":number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 2 Week 4; n=50	-0.79 (± 0.63)			
Part 2 Week 8; n=40	-0.78 (± 0.76)			
Part 2 Week 12; n=31	-0.85 (± 0.80)			
Part 2 Week 16; n=23	-0.67 (± 0.74)			
Part 2 Week 20; n=13	-0.93 (± 0.77)			
Part 2 Week 24; n=3	-0.96 (± 0.92)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in Number of Joints with Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Open-Label Baseline in Number of Joints with Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[33]
-----------------	--

End point description:

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Joints				
least squares mean (standard error)				
DB Week 4 (n=27,31)	-6.53 (± 0.34)	-7.39 (± 0.32)		

DB Week 8(n=25,25)	-6.36 (± 0.38)	-7.69 (± 0.38)		
DB Week 12 (n=21,23)	-5.92 (± 0.80)	-7.36 (± 0.76)		
DB Week 16 (n=21,20)	-7.34 (± 0.25)	-7.37 (± 0.25)		
DB Week 20 (n=19,15)	-7.41 (± 0.18)	-7.51 (± 0.20)		
DB Week 24 (n=18,15)	-7.33 (± 0.13)	-7.76 (± 0.13)		
DB Week 28 (n=17,12)	-6.36 (± 0.59)	-6.56 (± 0.67)		
DB Week 32 (n=13,10)	-7.27 (± 0.17)	-7.76 (± 0.19)		
DB Week 36 (n=13,10)	-7.43 (± 0.14)	-7.78 (± 0.16)		
DB Week 40(n=11,9)	-7.06 (± 0.24)	-7.58 (± 0.27)		
DB Week 44 (n=10, 9)	-7.39 (± 0.33)	-7.20 (± 0.35)		
DB Week 48 (n=8, 5)	-7.54 (± 0.20)	-7.75 (± 0.25)		
DB Week 52 (n=6, 5)	-7.46 (± 0.26)	-7.51 (± 0.28)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	1.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.79
upper limit	3.66

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	1.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.25
upper limit	2.4

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.08
upper limit	1.79

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.92

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.49

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.04
upper limit	1.03

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.09
upper limit	0.79

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.23
upper limit	1.28

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	0.83

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.49
upper limit	0.91

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	0.81

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	0.64

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.74

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.64
upper limit	2.06

Secondary: Change From Double-Blind Baseline in Number of Joints with Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind

Phase

End point title	Change From Double-Blind Baseline in Number of Joints with Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[34]
-----------------	--

End point description:

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. Participants were reported under the treatment they were randomised. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Joints				
least squares mean (standard error)				
DB Week 4 (n=27,31)	0.38 (± 0.26)	0.09 (± 0.24)		
DB Week 8 (n=25,25)	0.78 (± 0.38)	-0.23 (± 0.37)		
DB Week 12 (n=21,23)	1.47 (± 0.85)	0.22 (± 0.81)		
DB Week 16(n=21,20)	0.05 (± 0.27)	-0.05 (± 0.27)		
DB Week 20(n=19,15)	-0.15 (± 0.15)	-0.02 (± 0.17)		
DB Week 24 (n=18,15)	-0.06 (± 0.12)	-0.39 (± 0.13)		
DB Week 28 (n=17,12)	0.71 (± 0.70)	0.88 (± 0.84)		
DB Week 32 (n=13,10)	0.01 (± 0.18)	-0.41 (± 0.20)		
DB Week 36 (n=13,10)	-0.14 (± 0.15)	-0.47 (± 0.17)		
DB Week 40 (n=11,9)	0.31 (± 0.25)	-0.37 (± 0.28)		
DB Week 44(n=10, 9)	-0.05 (± 0.35)	0.11 (± 0.38)		
DB Week 48(n=8, 5)	-0.20 (± 0.21)	-0.56 (± 0.27)		
DB Week 52(n=6, 5)	-0.14 (± 0.28)	-0.38 (± 0.34)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
----------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
-------------------	--

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[35]
Parameter estimate	Difference in LS Mean
Point estimate	1.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.13
upper limit	3.64

Notes:

[35] - DB Week 12

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	2.08

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[36]
Parameter estimate	Difference in LS Mean
Point estimate	0.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	1

Notes:

[36] - DB Week 4

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[37]
Parameter estimate	Difference in LS Mean
Point estimate	0.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.03
upper limit	0.68

Notes:

[37] - DB Week 24

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[38]
Parameter estimate	Difference in LS Mean
Point estimate	-0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.58
upper limit	0.33

Notes:

[38] - DB Week 20

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[39]
Parameter estimate	Difference in LS Mean
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.68
upper limit	0.88

Notes:

[39] - DB Week 16

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[40]
Parameter estimate	Difference in LS Mean
Point estimate	-0.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.42
upper limit	2.08

Notes:

[40] - DB Week 28

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[41]
Parameter estimate	Difference in LS Mean
Point estimate	0.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.14
upper limit	0.97

Notes:

[41] - DB Week 32

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[42]
Parameter estimate	Difference in LS Mean
Point estimate	0.32

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.79

Notes:

[42] - DB Week 36

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[43]
Parameter estimate	Difference in LS Mean
Point estimate	0.68

Confidence interval

level	95 %
sides	2-sided
lower limit	-0.14
upper limit	1.49

Notes:

[43] - DB Week 40

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[44]
Parameter estimate	Difference in LS Mean
Point estimate	-0.16

Confidence interval

level	95 %
sides	2-sided
lower limit	-1.28
upper limit	0.96

Notes:

[44] - DB Week 44

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
-------------------	--

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[45]
Parameter estimate	Difference in LS Mean
Point estimate	0.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	1.16

Notes:

[45] - DB Week 48

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[46]
Parameter estimate	Difference in LS Mean
Point estimate	0.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.82
upper limit	1.3

Notes:

[46] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Secondary: Change From Open-Label Baseline in Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Open-Label Baseline in Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[47]
-----------------	--

End point description:

The parent was asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid. DBFAS set. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here "n"=number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
arithmetic mean (standard deviation)				
DB Week 4 (n=27,31)	-0.81 (± 0.10)	-1.03 (± 0.09)		
DB Week 8(n=25,25)	-0.93 (± 0.08)	-1.02 (± 0.08)		
DB Week 12 (n=21,23)	-0.99 (± 0.08)	-1.04 (± 0.07)		
DB Week 16(n=21,20)	-0.95 (± 0.09)	-1.05 (± 0.09)		
DB Week 20 (n=19,15)	-1.02 (± 0.07)	-1.21 (± 0.07)		
DB Week 24(n=18,15)	-0.94 (± 0.08)	-1.05 (± 0.08)		
DB Week 28(n=17,12)	-0.94 (± 0.08)	-1.01 (± 0.09)		
DB Week 32 (n=13,10)	-0.96 (± 0.07)	-1.11 (± 0.07)		
DB Week 36 (n=13,10)	-1.05 (± 0.08)	-1.16 (± 0.09)		
DB Week 40 (n=11,9)	-1.07 (± 0.07)	-1.22 (± 0.08)		
DB Week 44 (n=10, 9)	-1.04 (± 0.09)	-1.08 (± 0.09)		
DB Week 48(n=8, 5)	-1.01 (± 0.09)	-1.10 (± 0.11)		
DB Week 52 (n=6, 5)	-1.04 (± 0.10)	-1.13 (± 0.12)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[48]
Parameter estimate	Difference in LS Mean
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.32

Notes:

[48] - DB Week 8

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[49]
Parameter estimate	Difference in LS Mean
Point estimate	0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.07
upper limit	0.5

Notes:

[49] - DB Week 4

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[50]
Parameter estimate	Difference in LS Mean
Point estimate	0.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.17
upper limit	0.28

Notes:

[50] - DB Week 12

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[51]
Parameter estimate	Difference in LS Mean
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.16
upper limit	0.36

Notes:

[51] - DB Week 16

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[52]
Parameter estimate	Difference in LS Mean
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.12
upper limit	0.35

Notes:

[52] - DB Week 24

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[53]
Parameter estimate	Difference in LS Mean
Point estimate	0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.01
upper limit	0.38

Notes:

[53] - DB Week 20

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[54]
Parameter estimate	Difference in LS Mean
Point estimate	0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.18
upper limit	0.31

Notes:

[54] - DB Week 28

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[55]
Parameter estimate	Difference in LS Mean
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.38

Notes:

[55] - DB Week 40

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[56]
Parameter estimate	Difference in LS Mean
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.14
upper limit	0.36

Notes:

[56] - DB Week 36

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[57]
Parameter estimate	Difference in LS Mean
Point estimate	0.15

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.37

Notes:

[57] - DB Week 32

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[58]
Parameter estimate	Difference in LS Mean
Point estimate	0.04

Confidence interval

level	95 %
sides	2-sided
lower limit	-0.22
upper limit	0.3

Notes:

[58] - DB Week 44

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[59]
Parameter estimate	Difference in LS Mean
Point estimate	0.09

Confidence interval

level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.38

Notes:

[59] - DB Week 48

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
-------------------	--

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[60]
Parameter estimate	Difference in LS Mean
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.24
upper limit	0.42

Notes:

[60] - DB Week 52

Secondary: Change From Double Blind Baseline in Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Double Blind Baseline in Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[61]
-----------------	--

End point description:

The parent was asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid. DBFAS set. All participants reported under "Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here, "n" =number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[61] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
least squares mean (standard error)				
DB Week 4(n=27,31)	0.04 (± 0.06)	-0.02 (± 0.06)		
DB Week 8 (n=25,25)	-0.03 (± 0.06)	-0.01 (± 0.06)		
DB Week 12(n=21,23)	-0.06 (± 0.06)	-0.05 (± 0.06)		
DB Week 16(n=21,20)	-0.03 (± 0.07)	-0.05 (± 0.07)		
DB Week 20(n=19,15)	-0.08 (± 0.06)	-0.23 (± 0.06)		
DB Week 24 (n=18,15)	0.06 (± 0.08)	-0.09 (± 0.08)		
DB Week 28(n=17,12)	0.05 (± 0.08)	-0.04 (± 0.09)		
DB Week 32(n=13,10)	0.02 (± 0.07)	-0.13 (± 0.07)		
DB Week 36(n=13,10)	-0.03 (± 0.09)	-0.19 (± 0.09)		
DB Week 40 (n=11,9)	-0.09 (± 0.07)	-0.25 (± 0.07)		

DB Week 44 (n=10, 9)	-0.06 (± 0.09)	-0.10 (± 0.09)		
DB Week 48(n=8, 5)	-0.03 (± 0.09)	-0.19 (± 0.12)		
DB Week 52 (n=6, 5)	-0.05 (± 0.10)	-0.21 (± 0.13)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[62]
Parameter estimate	Difference in LS Mean
Point estimate	0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	0.24

Notes:

[62] - DB Week 4

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[63]
Parameter estimate	Difference in LS Mean
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.19
upper limit	0.15

Notes:

[63] - DB Week 8

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[64]
Parameter estimate	Difference in LS Mean
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.19
upper limit	0.16

Notes:

[64] - DB Week 12

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[65]
Parameter estimate	Difference in LS Mean
Point estimate	0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.23

Notes:

[65] - DB Week 16

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[66]
Parameter estimate	Difference in LS Mean
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.02
upper limit	0.32

Notes:

[66] - DB Week 20

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[67]
Parameter estimate	Difference in LS Mean
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.09
upper limit	0.4

Notes:

[67] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[68]
Parameter estimate	Difference in LS Mean
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.16
upper limit	0.34

Notes:

[68] - DB Week 28

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[69]
Parameter estimate	Difference in LS Mean
Point estimate	0.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.39

Notes:

[69] - DB Week 40

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[70]
Parameter estimate	Difference in LS Mean
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	0.43

Notes:

[70] - DB Week 36

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[71]
Parameter estimate	Difference in LS Mean
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.05
upper limit	0.36

Notes:

[71] - DB Week 32

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[72]
Parameter estimate	Difference in LS Mean
Point estimate	0.04

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.22
upper limit	0.3

Notes:

[72] - DB Week 44

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[73]
Parameter estimate	Difference in LS Mean
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.18
upper limit	0.49

Notes:

[73] - DB Week 48

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[74]
Parameter estimate	Difference in LS Mean
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.23
upper limit	0.55

Notes:

[74] - DB Week 52

Secondary: Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[75]
-----------------	---

End point description:

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

OL baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[75] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Joints				
least squares mean (standard error)				
DB Week 4 (n=27,31)	-2.47 (± 0.43)	-2.69 (± 0.41)		
DB Week 8 (n=25,25)	-2.31 (± 0.45)	-2.89 (± 0.44)		
DB Week 12(n=21,23)	-2.09 (± 0.71)	-3.29 (± 0.68)		
DB Week 16(n=21,20)	-2.76 (± 0.44)	-2.70 (± 0.43)		
DB Week 20(n=19,15)	-2.79 (± 0.19)	-3.05 (± 0.19)		
DB Week 24(n=18,15)	-2.98 (± 0.19)	-3.07 (± 0.19)		
DB Week 28(n=17,12)	-2.56 (± 0.54)	-2.10 (± 0.56)		
DB Week 32(n=13,10)	-2.89 (± 0.18)	-3.24 (± 0.19)		
DB Week 36(n=13,10)	-2.90 (± 0.19)	-3.21 (± 0.21)		
DB Week 40(n=11,9)	-2.96 (± 0.24)	-3.24 (± 0.25)		
DB Week 44(n=10,9)	-2.95 (± 0.25)	-3.24 (± 0.26)		
DB Week 48(n=8,5)	-3.03 (± 0.27)	-3.25 (± 0.30)		
DB Week 52(n=6,5)	-2.75 (± 0.36)	-3.20 (± 0.36)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.58

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.68
upper limit	1.84

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.97
upper limit	1.4

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.29
upper limit	0.82

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.46
upper limit	0.64

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.66
upper limit	1.57

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.18
upper limit	0.88

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 36	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.26
upper limit	0.88

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	0.99

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.45
upper limit	1.03

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.63
upper limit	1.08

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 16

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	1.18

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 12

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.77
upper limit	3.16

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.05
upper limit	1.13

Secondary: Change From Double-Blind Baseline in Number of Joints with Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Double-Blind Baseline in Number of Joints with Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[76]
-----------------	---

End point description:

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[76] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Joints				
least squares mean (standard error)				
DB Week 4 (n=27,31)	0.08 (± 0.22)	0.21 (± 0.20)		
DB Week 8 (n=25,25)	0.45 (± 0.42)	0.06 (± 0.42)		
DB Week 12 (n=21,23)	0.48 (± 0.44)	-0.23 (± 0.42)		
DB Week 16 (n=21,20)	-0.30 (± 0.17)	0.10 (± 0.17)		
DB Week 20 (n=19,15)	-0.36 (± 0.10)	-0.19 (± 0.11)		
DB Week 24(n=18,15)	-0.53 (± 0.10)	-0.22 (± 0.11)		
DB Week 28 (n=17,12)	-0.05 (± 0.40)	1.05 (± 0.46)		
DB Week 32 (n=13,10)	-0.41 (± 0.10)	-0.48 (± 0.12)		

DB Week 36 (n=13,10)	-0.48 ($\pm$ 0.09)	-0.46 ($\pm$ 0.10)		
DB Week 40 (n=11,9)	-0.48 ($\pm$ 0.15)	-0.43 ($\pm$ 0.17)		
DB Week 44 (n=10, 9)	-0.47 ($\pm$ 0.16)	-0.43 ($\pm$ 0.17)		
DB Week 48(n=8, 5)	-0.50 ($\pm$ 0.20)	-0.47 ($\pm$ 0.24)		
DB Week 52 (n=6, 5)	-0.21 ($\pm$ 0.31)	-0.42 ($\pm$ 0.33)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.73
upper limit	0.47

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.39
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.81
upper limit	1.59

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.54
upper limit	1.95

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	0.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.46
upper limit	0.13

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.63
upper limit	-0.01

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.34
upper limit	0.15

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.26
upper limit	0.4

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 36

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.26

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 40

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.53
upper limit	0.43

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.56
upper limit	0.46

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.74
upper limit	0.69

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.91
upper limit	1.32

Secondary: Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[77]
-----------------	---

End point description:

Physician global evaluation of disease activity was assessed on a VAS ranging from 0 to 10 mm, where 0=no activity and 10=maximum activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. Participants were reported under the treatment they were randomised. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[77] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
least squares mean (standard error)				
DB Week 4(n=27,31)	-4.22 (± 0.33)	-5.22 (± 0.32)		
DB Week 8 (n=25,25)	-4.23 (± 0.32)	-5.55 (± 0.32)		
DB Week 12(n=21,23)	-4.89 (± 0.36)	-5.42 (± 0.34)		
DB Week 16 (n=21,20)	-4.96 (± 0.32)	-5.22 (± 0.32)		
DB Week 20(n=19,15)	-5.32 (± 0.23)	-5.64 (± 0.24)		
DB Week 24 (n=18,15)	-5.11 (± 0.22)	-5.66 (± 0.23)		
DB Week 28 (n=17,12)	-5.06 (± 0.37)	-5.26 (± 0.40)		
DB Week 32 (n=13,10)	-5.08 (± 0.26)	-5.71 (± 0.28)		
DB Week 36 (n=13,10)	-5.55 (± 0.16)	-6.03 (± 0.18)		
DB Week 40 (n=11,9)	-5.23 (± 0.30)	-5.88 (± 0.33)		
DB Week 44(n=10, 9)	-5.65 (± 0.21)	-5.87 (± 0.22)		
DB Week 48(n=8, 5)	-5.87 (± 0.18)	-6.14 (± 0.24)		
DB Week 52 (n=6, 5)	-5.86 (± 0.26)	-5.97 (± 0.33)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.09
upper limit	1.92

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	1.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	2.22

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.47
upper limit	1.53

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.63
upper limit	1.16

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.33
upper limit	0.97

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Method	Mixed Model for Repeated Measures
Parameter estimate	Difference in LS Mean
Point estimate	0.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	1.2

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.93
upper limit	1.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.85

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 32

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.17
upper limit	1.42

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 36

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.02
upper limit	0.98

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	1.58

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.36
upper limit	0.88

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.87
upper limit	1.09

Secondary: Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[78]
-----------------	---

End point description:

Physician global evaluation of disease activity was assessed on a VAS ranging from 0 to 10 mm, where 0=no activity and 10=maximum activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. Participants were reported under the treatment they were randomised. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[78] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
least squares mean (standard error)				
DB Week 4 (n=27,31)	0.16 (± 0.25)	0.21 (± 0.24)		
DB Week 8(n=25,25)	0.45 (± 0.32)	-0.14 (± 0.32)		
DB Week 12 (n=21,23)	0.10 (± 0.40)	-0.02 (± 0.39)		
DB Week 16(n=21,20)	-0.11 (± 0.34)	0.15 (± 0.34)		
DB Week 20 (n=19,15)	-0.51 (± 0.22)	-0.35 (± 0.23)		
DB Week 24 (n=18,15)	-0.32 (± 0.22)	-0.37 (± 0.22)		
DB Week 28 (n=17,12)	0.09 (± 0.43)	0.19 (± 0.47)		
DB Week 32 (n=13,10)	-0.11 (± 0.29)	-0.42 (± 0.32)		
DB Week 36(n=13,10)	-0.74 (± 0.17)	-0.92 (± 0.18)		
DB Week 40 (n=11,9)	-0.17 (± 0.35)	-0.53 (± 0.37)		
DB Week 44 (n=10, 9)	-0.79 (± 0.21)	-0.70 (± 0.22)		
DB Week 48(n=8, 5)	-1.03 (± 0.20)	-1.09 (± 0.29)		
DB Week 52 (n=6, 5)	-1.00 (± 0.27)	-0.92 (± 0.39)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
----------------------------	---------------------------------------

Statistical analysis description:

DB Week 8

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.37
upper limit	1.53

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.77
upper limit	0.67

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.83
upper limit	0.52

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.61
upper limit	0.71

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 52

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0.94

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 32

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.61
upper limit	1.23

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.34
upper limit	0.71

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.74
upper limit	1.46

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.75
upper limit	0.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.68
upper limit	0.81

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.27
upper limit	0.74

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.12

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.06
upper limit	1.3

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.45
upper limit	1.25

Secondary: Change From Open-Label Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Open-Label Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[79]
-----------------	---

End point description:

DBFAS was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[79] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Double-Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Millimeter per hour (mm/h)				
least squares mean (standard error)				
DB Week 4 (n=27,31)	-32.65 (± 4.72)	-31.19 (± 4.49)		

DB Week 8(n=25,25)	-36.55 (± 4.38)	-29.32 (± 4.29)		
DB Week 12(n=21,23)	-38.30 (± 4.50)	-31.69 (± 4.35)		
DB Week 16(n=21,20)	-39.52 (± 4.06)	-31.02 (± 4.06)		
DB Week 20 (n=19,15)	-41.82 (± 2.22)	-37.86 (± 2.32)		
DB Week 24(n=18,15)	-42.25 (± 2.25)	-40.81 (± 2.33)		
DB Week 28 (n=17,12)	-37.83 (± 4.07)	-33.51 (± 4.39)		
DB Week 32 (n=13,10)	-37.90 (± 3.67)	-35.04 (± 3.91)		
DB Week 36 (n=13,10)	-39.36 (± 4.49)	-28.41 (± 4.79)		
DB Week 40(n=11,9)	-39.98 (± 4.12)	-35.70 (± 4.31)		
DB Week 44 (n=10, 9)	-47.16 (± 2.28)	-38.84 (± 2.34)		
DB Week 48 (n=8, 5)	-47.16 (± 2.29)	-42.32 (± 2.72)		
DB Week 52 (n=6, 4)	-51.46 (± 1.08)	-50.12 (± 1.24)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-7.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.62
upper limit	5.17

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.59
upper limit	11.66

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-8.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.28
upper limit	3.27

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-4.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.67
upper limit	8.03

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.09
upper limit	5.21

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-3.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.53
upper limit	2.62

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-6.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.36
upper limit	6.14

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 52

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.16
upper limit	2.48

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-4.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.6
upper limit	2.92

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-8.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.2
upper limit	-1.43

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-10.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.63
upper limit	2.73

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-2.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.97
upper limit	8.25

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-4.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.74
upper limit	8.18

Secondary: Change From Double-Blind Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Double-Blind Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[80]
-----------------	---

End point description:

DBFAS set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[80] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Millimeter/ hour (mm/h)				
least squares mean (standard error)				
DB Week 4 (n=27,30)	3.35 (± 3.71)	9.41 (± 3.50)		
DB Week 8 (n=25,24)	1.94 (± 3.97)	12.39 (± 3.93)		
DB Week 12 (n=21,22)	1.42 (± 4.53)	12.28 (± 4.40)		
DB Week 16(n=21,19)	0.45 (± 4.32)	13.59 (± 4.35)		
DB Week 20(n=19,14)	-2.04 (± 2.17)	4.98 (± 2.31)		
DB Week 24(n=18,14)	-2.51 (± 2.14)	2.01 (± 2.28)		
DB Week 28(n=17,12)	1.73 (± 4.19)	11.08 (± 4.55)		
DB Week 32(n=13,10)	2.01 (± 3.78)	8.77 (± 4.05)		
DB Week 36(n=13,10)	0.88 (± 4.83)	16.37 (± 5.17)		
DB Week 40(n=11,9)	0.34 (± 4.25)	8.33 (± 4.47)		
DB Week 44(n=10,9)	-7.05 (± 2.34)	3.44 (± 2.41)		
DB Week 48(n=8,5)	-8.07 (± 2.38)	-2.14 (± 2.96)		
DB Week 52(n=6,4)	-11.70 (± 1.39)	-9.14 (± 1.73)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
----------------------------	---------------------------------------

Statistical analysis description:

DB Week 40

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
-------------------	--

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-7.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21
upper limit	5.03

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-6.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.3
upper limit	4.19

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-10.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.68
upper limit	0.77

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-10.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.75
upper limit	2.03

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-13.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.83
upper limit	-0.46

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-7.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.56
upper limit	-0.47

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-4.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11
upper limit	1.95

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 28

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-9.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.24
upper limit	3.54

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 32

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-6.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.34
upper limit	4.83

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-15.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.36
upper limit	-0.63

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-10.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.67
upper limit	-3.31

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-5.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.53
upper limit	1.67

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-2.57
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.37
upper limit	1.24

Secondary: Change From Open-Label Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Open-Label Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[81]
-----------------	---

End point description:

The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= Very Well' and '10=Very Poorly. DBFAS set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[81] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double-Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
least squares mean (standard error)				
DB Week 4 (n=27,30)	-4.31 (± 0.37)	-5.52 (± 0.34)		
DB Week 8 (n=25,25)	-4.56 (± 0.36)	-5.38 (± 0.35)		
DB Week 12(n=21,23)	-4.97 (± 0.34)	-5.28 (± 0.33)		

DB Week 16(n=21,20)	-4.88 (± 0.29)	-5.46 (± 0.29)		
DB Week 20 (n=19,15)	-5.19 (± 0.32)	-5.36 (± 0.34)		
DB Week 24 (n=18,15)	-4.97 (± 0.29)	-5.62 (± 0.30)		
DB Week 28(n=17,12)	-5.08 (± 0.44)	-5.00 (± 0.48)		
DB Week 32 (n=13,10)	-5.63 (± 0.18)	-5.55 (± 0.20)		
DB Week 36 (n=13,10)	-5.81 (± 0.18)	-5.87 (± 0.21)		
DB Week 40 (n=11,9)	-5.98 (± 0.16)	-5.94 (± 0.18)		
DB Week 44 (n=10, 9)	-5.95 (± 0.21)	-5.79 (± 0.23)		
DB Week 48 (n=8, 5)	-5.45 (± 0.31)	-5.30 (± 0.57)		
DB Week 52 (n=6, 5)	-6.06 (± 0.25)	-5.98 (± 0.43)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.18
upper limit	1.49

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.78
upper limit	1.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 16

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.57
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.26
upper limit	1.41

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 12

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.65
upper limit	1.27

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 8

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	1.85

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	2.22

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.51
upper limit	1.22

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.82
upper limit	0.5

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.55
upper limit	0.47

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.51
upper limit	0.63

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.07

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.65
upper limit	0.5

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.05
upper limit	0.88

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.43
upper limit	1.27

Secondary: Change From Double-Blind Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Double-Blind Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[82]
-----------------	---

End point description:

The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-

being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= Very Well' and '10'=Very Poorly. DBFAS set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[82] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
least squares mean (standard error)				
DB Week 4 (n=27,30)	0.46 (± 0.28)	-0.03 (± 0.27)		
DB Week 8 (n=25,25)	0.60 (± 0.38)	0.12 (± 0.38)		
DB Week 12 (n=21,23)	0.25 (± 0.36)	0.22 (± 0.35)		
DB Week 16 (n=21,20)	0.27 (± 0.31)	0.04 (± 0.31)		
DB Week 20 (n=19,15)	0.14 (± 0.37)	0.05 (± 0.38)		
DB Week 24 (n=18,15)	0.14 (± 0.29)	-0.14 (± 0.30)		
DB Week 28 (n=17,12)	0.54 (± 0.52)	0.52 (± 0.56)		
DB Week 32 (n=13,10)	-0.32 (± 0.24)	-0.34 (± 0.25)		
DB Week 36 (n=13,10)	-0.56 (± 0.21)	-0.63 (± 0.22)		
DB Week 40 (n=11,9)	-0.72 (± 0.19)	-0.78 (± 0.20)		
DB Week 44 (n=10,9)	-0.65 (± 0.24)	-0.54 (± 0.25)		
DB Week 48 (n=8,5)	-0.16 (± 0.36)	-0.37 (± 0.53)		
DB Week 52 (n=6,5)	-0.82 (± 0.26)	-0.87 (± 0.38)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.32
upper limit	1.3

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.64
upper limit	1.61

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.02
upper limit	1.07

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.23

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.69
upper limit	1.14

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.05
upper limit	1.22

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	1.16

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	1.64

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.58
upper limit	0.73

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	1.64

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.53
upper limit	0.65

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.13
upper limit	1.54

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.87
upper limit	0.64

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 52

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	1.11

Secondary: Change From Open-Label Baseline in Child Health Questionnaire (CHQ) Responses at End of Open-label Phase Part 1

End point title	Change From Open-Label Baseline in Child Health Questionnaire (CHQ) Responses at End of Open-label Phase Part 1 ^[83]
-----------------	---

End point description:

The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions, physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4–6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. OLPT1 analysis set was used. All participants reported under Number of subjects analysed" contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

OL Baseline up to 16 weeks

Notes:

[83] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Global Health Subscale Standardized Score n=85	26.12 (± 29.10)			
Physical Functioning Standardized Score n=85	28.95 (± 33.79)			
Social Limitations: Emotional Score n=84	27.51 (± 38.39)			
Social Limitations: Physical Score n=84	31.15 (± 42.96)			

Bodily Pain Subscale Standardized Score n=85	32.00 (± 26.67)			
Behavior Subscale Standardized Score n=85	10.98 (± 17.14)			
Global Behavior Subscale Standardized Score n=85	11.18 (± 27.75)			
Mental Health Subscale Standardized Score n=84	13.33 (± 20.20)			
Self Esteem Subscale Standardized Score n=83	7.68 (± 21.29)			
General Health Subscale Score n=85	8.37 (± 13.93)			
Change in Health Subscale Score n=85	1.28 (± 1.10)			
Emotional Impact on Parent Subscale Score n=85	12.75 (± 26.43)			
Time Impact on Parent Standardized Score n=84	14.81 (± 28.62)			
Family Activities Standardized Score n=84	74.03 (± 22.41)			
Family Cohesion Standardized Score n=84	8.10 (± 22.67)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-Label Baseline in CHQ Responses at End of Open-label Phase Part 2

End point title	Change From Open-Label Baseline in CHQ Responses at End of Open-label Phase Part 2 ^[84]
-----------------	--

End point description:

The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions, physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4–6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. OLPT2 analysis set was used. "Number of subjects analysed" =participants evaluable for the endpoint and "n" =number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) up to 24 weeks

Notes:

[84] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Global Health Standardized Score n=29	25.52 (± 35.46)			

Physical Functioning Standardized Score n=29	33.33 (± 31.29)			
Social Limitations: Emotional Score n=28	28.17 (± 43.98)			
Social Limitations: Physical Score n=28	38.10 (± 42.28)			
Bodily Pain Standardized Score n=29	34.48 (± 26.80)			
Behavior Standardized Score n=29	13.02 (± 21.14)			
Global Behavior Standardized Score n=29	10.00 (± 34.10)			
Mental Health Standardized Score n=28	18.04 (± 21.01)			
Self Esteem Standardized Score n=27	8.30 (± 34.18)			
General Health Standardized Score n=28	8.18 (± 15.94)			
Change in Health Subscale Score n=28	1.54 (± 1.23)			
Emotional Impact on Parent Standardized Score n=28	22.92 (± 36.33)			
Time Impact on Parent Standardized Score n=27	34.57 (± 25.66)			
Family Activities Standardized Score n=27	27.62 (± 25.87)			
Family Cohesion Standardized Score n=27	10.00 (± 23.25)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Double-Blind Baseline in CHQ Responses at DB Weeks 24, 48: Double-Blind Phase

End point title	Change From Double-Blind Baseline in CHQ Responses at DB Weeks 24, 48: Double-Blind Phase ^[85]
-----------------	---

End point description:

The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions, physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4–6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. DBFAS analysis set was used. "Number of subjects analysed" =participants evaluable for the endpoint and "n" =number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (values at randomization), DB Weeks 24, 48

Notes:

[85] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	15		
Units: Units on a scale				
least squares mean (standard error)				
Global Health Score:Week 24 n=(17,15)	4.02 (± 4.71)	-1.98 (± 5.02)		
Global Health Score:Week 48 n=(5,4)	4.09 (± 3.93)	1.24 (± 4.49)		
Physical Functioning Score:Week 24 n=(17,15)	2.51 (± 3.86)	6.70 (± 3.99)		
Physical Functioning Score:Week 48 n=(5,4)	5.24 (± 9.13)	2.93 (± 14.02)		
Social Limitation:Emotional Score:Week24 n=(17,15)	2.62 (± 4.00)	8.09 (± 4.18)		
Social Limitation:Emotional Score:Week48 n=(5,4)	6.09 (± 7.69)	-0.73 (± 10.33)		
Social Limitations:Physical Score:Week24 n=(17,15)	2.75 (± 4.27)	8.98 (± 4.54)		
Social Limitations:Physical Score:Week48 n=(5,4)	3.45 (± 13.33)	-7.64 (± 20.06)		
Bodily Pain Score:Week 24 n=(17,15)	-1.61 (± 4.19)	-0.16 (± 4.41)		
Bodily Pain Score:Week 48 n=(5,4)	-2.72 (± 10.19)	-19.92 (± 13.98)		
Behavior Score:Week 24 n=(17,15)	2.33 (± 2.68)	7.48 (± 2.87)		
Behavior Score:Week 48 n=(5,4)	-4.50 (± 4.97)	10.53 (± 5.35)		
Global Behavior Score:Week 24 n=(17,15)	4.17 (± 3.89)	9.48 (± 4.13)		
Global Behavior Score:Week48 n=(5,4)	5.90 (± 4.00)	13.14 (± 4.54)		
Mental Health Score:Week 24 n=(17,15)	6.59 (± 3.56)	2.14 (± 3.78)		
Mental Health Score:Week48 n=(5,4)	0.79 (± 4.98)	8.26 (± 5.71)		
Self Esteem Score:Week 24 n=(17,15)	6.68 (± 3.05)	6.69 (± 3.24)		
Self Esteem Score:Week 48 n=(5,4)	3.05 (± 7.24)	10.64 (± 8.04)		
General Health Score:Week 24 n=(17,15)	5.02 (± 3.21)	0.03 (± 3.42)		
General Health Score:Week 48 n=(5,4)	9.59 (± 5.20)	10.60 (± 5.92)		
Change in Health Score:Week 24 n=(17,15)	0.45 (± 0.12)	0.48 (± 0.13)		
Change in Health Score:Week48 n=(5,4)	0.64 (± 0.32)	0.16 (± 0.35)		
Emotional Impact on Parent Score:Week 24 n=(17,15)	15.00 (± 4.28)	12.75 (± 4.53)		
Emotional Impact on Parent Score:Week 48 n=(5,4)	7.15 (± 10.25)	32.22 (± 11.79)		
Time Impact on Parent Score Week 24 n=(17,15)	7.53 (± 5.10)	5.66 (± 5.25)		
Time Impact on Parent Score Week 48 n=(5,4)	11.60 (± 8.94)	20.79 (± 14.05)		
Family Activities Score:Week 24 n=(17,15)	5.71 (± 2.96)	9.68 (± 3.13)		
Family Activities Score:Week 48 n=(5,4)	6.65 (± 5.73)	15.95 (± 7.16)		
Family Cohesion Score:Week 24 n=(17,15)	2.84 (± 3.71)	6.36 (± 3.96)		
Family Cohesion Score:Week 48 n=(5,4)	-12.24 (± 13.08)	8.18 (± 15.58)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Physical Subscale score: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-6.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.95
upper limit	6.5

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Emotional Subscale score:DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	6.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.92
upper limit	34.57

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Emotional Subscale score:DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-5.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.37
upper limit	6.43

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Physical Functioning Score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	2.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.06
upper limit	41.68

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Physical Functioning Score: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-4.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.78
upper limit	7.4

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Global Health Score: DB Week 48	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	2.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.43
upper limit	18.14

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Global Health Score: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.35
upper limit	20.36

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Global Behavior score:DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-7.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.35
upper limit	5.87

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Global Behavior score:DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-5.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.92
upper limit	6.29

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

Behavior Subscale score:DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-15.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.12
upper limit	3.06

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

Behavior Subscale score:DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-5.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.24
upper limit	2.93

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Bodily Pain Subscale score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	17.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.01
upper limit	62.41

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Bodily Pain Subscale score: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.97
upper limit	11.06

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Physical Subscale score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	11.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-46.24
upper limit	68.42

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Mental Health score: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	4.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.18
upper limit	15.07

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: General Health Subscale score:DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	4.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.81
upper limit	14.77

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Self Esteem Subscale score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-7.59

Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.87
upper limit	18.7

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Self Esteem Subscale score: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.14
upper limit	9.13

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: Mental Health score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-7.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.37
upper limit	9.45

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: General Health Subscale score:DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.31
upper limit	18.28

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Health Subscale Score: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.33

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Health Subscale Score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.68
upper limit	1.65

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Emotional Impact on Parent Subscale score: DB Week 24	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	2.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.59
upper limit	15.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Emotional Impact on Parent Subscale score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-25.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-60.96
upper limit	10.82

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Family Cohesion Subscale Score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-20.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-79.03
upper limit	38.18

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

Family Cohesion Subscale Score: DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-3.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.84
upper limit	7.81

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

Family Activities Subscale Score: DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-9.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.35
upper limit	13.75

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

Family Activities Subscale Score: DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-3.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.84
upper limit	4.9

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Time Impact on Parent Subscale score: DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-9.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-48.91
upper limit	30.53

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
Time Impact on Parent Subscale score: DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	1.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.55
upper limit	17.29

Secondary: Change From Open-Label Baseline in CHAQ-Discomfort Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Change From Open-Label Baseline in CHAQ-Discomfort Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[86]
End point description:	
For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'No pain' and '10' as 'Very severe pain' on a 21-circle VAS. OLPT1 analysis set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, "n" signifies number of participants evaluable for specified rows.	
End point type	Secondary
End point timeframe:	
Baseline ((last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Day 7, Weeks 2, 4, 8, 12, 16	

Notes:

[86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 1 Day 7, n=99	-1.20 (± 1.77)			
Part 1 Week 2, n=98	-1.87 (± 2.07)			
Part 1 Week 4, n=97	-2.57 (± 2.14)			
Part 1 Week 8, n=82	-3.30 (± 2.45)			
Part 1 Week 12, n=44	-3.57 (± 2.50)			
Part 1 Week 16, n=24	-3.69 (± 2.28)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Open-label Baseline in CHAQ-Discomfort Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Change From Open-label Baseline in CHAQ-Discomfort Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[87]
-----------------	--

End point description:

For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'No pain' and '10' as 'very severe pain' on a 21-circle VAS. OLPT2 analysis set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here "Number Analysed" signifies number of participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[87] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Part 2 Week 4, n=50	-4.23 (± 3.14)			
Part 2 Week 8, n=40	-4.38 (± 2.95)			

Part 2 Week 12,n=31	-4.42 (± 3.26)			
Part 2 Week 16,n=23	-4.48 (± 2.88)			
Part 2 Week 20,n=13	-5.15 (± 3.52)			
Part 2 Week 24,n=3	-6.00 (± 1.73)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Double-Blind Baseline in CHAQ-Discomfort Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Change From Double-Blind Baseline in CHAQ-Discomfort Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[88]
-----------------	---

End point description:

For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'No pain' and '10' as 'very severe pain' on a 21-circle VAS. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. Missing response was imputed as non-response.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[88] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Units on a scale				
least squares mean (standard error)				
DB Week 4(n=27,30)	0.13 (± 0.28)	0.37 (± 0.26)		
DB Week 8 (n=25,25)	0.56 (± 0.36)	0.02 (± 0.35)		
DB Week 12(n=21,23)	0.04 (± 0.34)	0.09 (± 0.32)		
DB Week 16 (n=21,20)	0.44 (± 0.36)	-0.11 (± 0.35)		
DB Week 20 (n=19,15)	0.09 (± 0.40)	-0.14 (± 0.42)		
DB Week 24 (n=18,15)	0.07 (± 0.27)	-0.25 (± 0.28)		
DB Week 28 (n=17,12)	-0.03 (± 0.47)	0.39 (± 0.51)		
DB Week 32(n=13,10)	-0.31 (± 0.39)	0.01 (± 0.42)		
DB Week 36(n=13,10)	-0.55 (± 0.34)	-0.24 (± 0.37)		
DB Week 40(n=11,9)	-0.76 (± 0.20)	-0.83 (± 0.21)		
DB Week 44 (n=10, 9)	-1.09 (± 0.23)	-0.79 (± 0.24)		
DB Week 48 (n=8, 5)	-0.19 (± 0.49)	-0.43 (± 0.79)		
DB Week 52 (n=6, 5)	-0.85 (± 0.21)	-0.76 (± 0.34)		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.02
upper limit	0.54

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.01
upper limit	0.9

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.49
upper limit	1.58

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.98
upper limit	1.45

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.51
upper limit	1.14

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.87
upper limit	0.69

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.53
upper limit	0.88

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.36
upper limit	0.74

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 40

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.55
upper limit	0.69

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.01
upper limit	0.39

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.45
upper limit	1.92

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.49
upper limit	1.57

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	-0.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.87
upper limit	1.03

Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

End point title	Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 ^[89]
End point description:	
Minimal disease activity is defined as follows: Polyarthrititis (>4 active joints): Minimal Disease Activity: less than equal (<=) 3.8. Oligoarthritis (<= 4 active joints): Minimal Disease Activity: <=2. OLPT1 analysis set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.	
End point type	Secondary
End point timeframe:	
Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16	

Notes:

[89] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 1 Day 7; n=97	3.09 (0 to 6.54)			
Part 1 Week 2; n=96	5.21 (0.76 to 9.65)			
Part 1 Week 4; n=97	6.19 (1.39 to 10.98)			
Part 1 Week 8; n=80	13.75 (6.20 to 21.30)			
Part 1 Week 12; n=44	13.64 (3.50 to 23.78)			
Part 1 Week 16; n=24	25.00 (7.68 to 42.32)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

End point title	Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 ^[90]
-----------------	--

End point description:

Minimal disease activity is defined as follows: Polyarthrititis (>4 active joints): Minimal Disease Activity: less than equal ($\leq$) 3.8. Oligoarthritis ($\leq$ 4 active joints): Minimal Disease Activity: $\leq$ 2. OLPT1 analysis set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1 Day 7, Weeks 2, 4, 8, 12 and 16

Notes:

[90] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 1 Day 7: n=98	1.02 (0 to 3.01)			
Part 1 Week 2: n=98	4.08 (0.16 to 8.00)			
Part 1 Week 4: n=97	7.22 (2.07 to 12.37)			
Part 1 Week 8: n=81	14.81 (7.08 to 22.55)			
Part 1 Week 12: n=44	15.91 (5.10 to 26.72)			
Part 1 Week 16: n=24	20.83 (4.59 to 37.08)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[91]
-----------------	---

End point description:

Minimal disease activity is defined as follows: Polyarthrititis (>4 active joints): Minimal Disease Activity: less than equal ($\leq$) 3.8. Oligoarthrititis ($\leq$ 4 active joints): Minimal Disease Activity: $\leq$ 2. OLPT2 analysis set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[91] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 2 Week 4; n=50	36.00 (22.70 to 49.30)			
Part 2 Week 8; n=40	30.00 (15.80 to 44.20)			

Part 2 Week 12; n=31	32.26 (15.80 to 48.71)			
Part 2 Week 16; n=22	36.36 (16.26 to 56.47)			
Part 2 Week 20; n=13	53.85 (26.75 to 80.95)			
Part 2 Week 24; n=3	33.33 (0 to 86.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

End point title	Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 ^[92]
-----------------	---

End point description:

Inactive Disease activity is defined as based on JADAS 27 score follows: Polyarthrititis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. OLPT1 set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1 Day 7, Weeks 2, 4, 8, 12 and 16

Notes:

[92] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of Participants				
number (confidence interval 95%)				
Part 1 Day 7; n=97	0 (0 to 0)			
Part 1 Week 2; n=96	3.13 (0 to 6.61)			
Part 1 Week 4; n=97	3.09 (0 to 6.54)			
Part 1 Week 8; n=80	5.00 (0.22 to 9.78)			
Part 1 Week 12; n=44	4.55 (0 to 10.70)			
Part 1 Week 16; n=24	4.17 (0 to 12.16)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[93]
-----------------	---

End point description:

Minimal disease activity is defined as follows: Polyarthrititis (>4 active joints): Minimal Disease Activity: less than equal ($\leq$) 3.8. Oligoarthritis ($\leq$ 4 active joints): Minimal Disease Activity: $\leq$ 2. OLPT2 analysis set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[93] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 2 Week 4; n=50	32.00 (19.07 to 44.93)			
Part 2 Week 8; n=40	27.50 (13.66 to 41.34)			
Part 2 Week 12; n=31	29.03 (13.05 to 45.01)			
Part 2 Week 16; n=23	34.78 (15.32 to 54.25)			
Part 2 Week 20; n=13	53.85 (26.75 to 80.95)			
Part 2 Week 24; n=3	33.33 (0 to 86.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

End point title	Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 ^[94]
-----------------	---

End point description:

Inactive disease activity is defined as based on JADAS 27 score follows: Polyarthrititis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. OLPT1 set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1 Day 7, Weeks 2, 4, 8, 12 and 16

Notes:

[94] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of Participants				
number (confidence interval 95%)				
Part 1 Day 7; n=98	0 (0 to 0)			
Part 1 Week 2; n=98	2.04 (0 to 4.84)			
Part 1 Week 4; n=97	1.03 (0 to 3.04)			
Part 1 Week 8; n=81	3.70 (0 to 7.82)			
Part 1 Week 12; n=44	6.82 (0 to 14.27)			
Part 1 Week 16; n=24	4.17 (0 to 12.16)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[95]
-----------------	--

End point description:

Inactive disease activity is defined as based on JADAS 27 score follows: Polyarthrititis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. OLPT2 set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
End point timeframe:	
Part 2 Weeks 4, 8, 12, 16, 20, 24	
Notes:	
[95] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.	

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of Participants				
number (confidence interval 95%)				
Part 2 Week 4; n=50	16.00 (5.84 to 26.16)			
Part 2 Week 8; n=40	20.00 (7.60 to 32.40)			
Part 2 Week 12; n=31	9.68 (0 to 20.09)			
Part 2 Week 16; n=22	18.18 (2.06 to 34.30)			
Part 2 Week 20; n=13	38.46 (12.01 to 64.91)			
Part 2 Week 24; n=3	33.33 (0 to 86.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 ^[96]
-----------------	--

End point description:

Inactive Disease activity is defined as based on JADAS 27 score follows: Polyarthrititis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. OLPT2 set was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
End point timeframe:	
Part 2 Weeks 4, 8, 12, 16, 20, 24	
Notes:	
[96] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.	

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of Participants				
number (confidence interval 95%)				
Part 2 Week 4; n=50	16.00 (5.84 to 26.16)			
Part 2 Week 8; n=40	17.50 (5.72 to 29.28)			
Part 2 Week 12; n=31	9.68 (0 to 20.09)			
Part 2 Week 16; n=23	17.39 (1.90 to 32.88)			
Part 2 Week 20; n=13	46.15 (19.05 to 73.25)			
Part 2 Week 24; n=3	33.33 (0 to 86.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[97]
-----------------	--

End point description:

Minimal disease activity is defined as follows: Polyarthrititis (>4 active joints): Minimal Disease Activity: less than equal ($\leq$) 3.8. Oligoarthrititis ($\leq$ 4 active joints): Minimal Disease Activity: $\leq$ 2. DBFAS analysis set was used. Missing response was imputed as non-response.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Notes:

[97] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Percentage of Participants				
number (not applicable)				
DB Week 4	21.43	51.61		
DB Week 8	25.00	48.39		
DB Week 12	32.14	32.26		
DB Week 16	35.71	29.03		
DB Week 20	35.71	22.58		

DB Week 24	35.71	35.48		
DB Week 28	35.71	32.26		
DB Week 32	28.57	22.58		
DB Week 36	39.29	35.48		
DB Week 40	39.29	29.03		
DB Week 44	46.43	25.81		
DB Week 48	46.43	25.81		
DB Week 52	46.43	29.03		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.99
upper limit	23.76

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-23.39
Confidence interval	
level	95 %
sides	2-sided
lower limit	-47.19
upper limit	0.42

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-30.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	-53.43
upper limit	-6.94

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	17.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.03
upper limit	41.82

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	5.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.29
upper limit	28.28

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 36

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.92
upper limit	28.52

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 40

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	10.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.88
upper limit	34.39

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 44

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	20.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.43
upper limit	44.67

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	20.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.43
upper limit	44.67

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.24
upper limit	24.7

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	13.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.92
upper limit	36.19

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	6.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.2
upper limit	30.56

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	3.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.75
upper limit	27.66

Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[98]
End point description:	
Minimal disease activity is defined as follows: Polyarthrititis (>4 active joints): Minimal Disease Activity: less than equal (<=) 3.8. Oligoarthritis (<= 4 active joints): Minimal Disease Activity: <=2. DBFAS analysis set was used. Missing response was imputed as non-response.	
End point type	Secondary
End point timeframe:	
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52	

Notes:

[98] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Percentage of Participants				
number (not applicable)				
DB Week 4	25.00	51.61		
DB Week 8	25.00	45.16		
DB Week 12	32.14	41.94		
DB Week 16	35.71	35.48		
DB Week 20	39.29	29.03		
DB Week 24	35.71	38.71		
DB Week 28	35.71	38.71		
DB Week 32	28.57	35.48		
DB Week 36	39.29	35.48		
DB Week 40	39.29	32.26		
DB Week 44	50.00	32.26		
DB Week 48	50.00	35.48		
DB Week 52	50.00	32.26		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-26.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	-50.42
upper limit	-2.81

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-20.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-43.91
upper limit	3.59

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-9.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.31
upper limit	14.72

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.24
upper limit	24.7

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 20

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	10.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.88
upper limit	34.39

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.67
upper limit	21.68

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 28

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.67
upper limit	21.68

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-6.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.65
upper limit	16.83

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.92
upper limit	28.52

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	7.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.43
upper limit	31.48

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	17.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.03
upper limit	42.52

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	14.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.52
upper limit	39.55

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	17.74

Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.03
upper limit	42.52

Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[99]
-----------------	---

End point description:

Inactive disease activity is defined as based on JADAS 27 score follows: Polyarthritis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. DBFAS set was used. Missing response was imputed as non-response.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Notes:

[99] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Percentage of Participants				
number (not applicable)				
DB Week 4	10.71	25.81		
DB Week 8	7.14	19.35		
DB Week 12	7.14	16.13		
DB Week 16	14.29	9.68		
DB Week 20	14.29	9.68		
DB Week 24	7.14	16.13		
DB Week 28	10.71	22.58		
DB Week 32	14.29	19.35		
DB Week 36	10.71	16.13		
DB Week 40	14.29	25.81		
DB Week 44	14.29	16.13		
DB Week 48	10.71	19.35		
DB Week 52	14.29	19.35		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-15.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.29
upper limit	4.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.07
upper limit	7.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	4.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.01
upper limit	21.23

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	4.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.01
upper limit	21.23

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.07
upper limit	7.1

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-12.21

Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.08
upper limit	4.65

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-11.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.52
upper limit	6.79

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-5.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.08
upper limit	13.94

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-5.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.7
upper limit	11.87

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-11.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.65
upper limit	8.61

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-1.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.16
upper limit	16.48

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.66
upper limit	9.38

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-5.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.08
upper limit	13.94

Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[100]
-----------------	--

End point description:

Inactive disease activity is defined as based on JADAS 27 score follows: Polyarthrititis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. DBFAS set was used. Missing response was imputed as non-response.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Notes:

[100] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Percentage of Participants				
number (not applicable)				
DB Week 4	7.14	19.35		
DB Week 8	14.29	29.03		
DB Week 12	14.29	22.58		
DB Week 16	17.86	16.13		
DB Week 20	14.29	12.90		
DB Week 24	10.71	16.13		
DB Week 28	10.71	22.58		
DB Week 32	14.29	19.35		
DB Week 36	10.71	19.35		
DB Week 40	14.29	25.81		
DB Week 44	14.29	22.58		
DB Week 48	14.29	22.58		
DB Week 52	14.29	19.35		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 8	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-14.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.32
upper limit	5.83

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 4	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-12.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.08
upper limit	4.65

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 12	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.91
upper limit	11.32

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-11.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.52
upper limit	6.79

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 32	

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-5.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.08
upper limit	13.94

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.66
upper limit	9.38

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.91
upper limit	11.32

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

DB Week 48

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-8.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.91
upper limit	11.32

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 52

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-5.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.08
upper limit	13.94

Statistical analysis title

Tofacitinib 5mg BID DB and Placebo DB

Statistical analysis description:

DB Week 24

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-5.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.7
upper limit	11.87

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 20	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	1.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.15
upper limit	18.91

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 16	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	1.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.48
upper limit	20.93

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-11.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.65
upper limit	8.61

Secondary: Percentage of Participants with JIA ACR Inactive Disease Status at Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

End point title	Percentage of Participants with JIA ACR Inactive Disease Status at Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 ^[101]
-----------------	--

End point description:

The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the scale used; duration of morning stiffness of ≤15 minutes. 95% CI was based on normal approximation. OLPT1 set was used. n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline ((last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16

Notes:

[101] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID Open_Label (OL) Part 1			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: Percentage of Participants				
number (confidence interval 95%)				
Baseline; n=100	0 (0 to 0)			
Part 1 Day 3; n=96	0 (0 to 0)			
Part 1 Day 7; n=99	0 (0 to 0)			
Part 1 Week 2; n=99	2.02 (0 to 4.79)			
Part 1 Week 4; n=97	3.09 (0 to 6.54)			
Part 1 Week 8; n=83	4.82 (0.21 to 9.43)			
Part 1 Week 12; n=44	4.55 (0 to 10.70)			
Part 1 Week 16; n=24	4.17 (0 to 12.16)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with JIA ACR Inactive Disease Status at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

End point title	Percentage of Participants with JIA ACR Inactive Disease Status
-----------------	---

End point description:

The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the scale used; duration of morning stiffness of ≤ 15 minutes. 95% CI was based on normal approximation. OLPT2 was used. All participants reported under 'Number of Participants Analysed' contributed data to the table; however, may not have evaluable data for every row. n=number of participants evaluable for the specified time points and used for calculating percentages.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 2 Weeks 4, 8, 12, 16, 20, 24

Notes:

[102] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.

End point values	Tofacitinib 5mg BID OL Part 2			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: Percentage of participants				
number (confidence interval 95%)				
Part 2 Week 4;n=50	14.00 (4.38 to 23.62)			
Part 2 Week 8;n=39	10.26 (0.73 to 19.78)			
Part 2 Week 12;n=31	6.45 (0 to 15.10)			
Part 2 Week 16;n=23	13.04 (0 to 26.81)			
Part 2 Week 20;n=13	15.38 (0 to 35.00)			
Part 2 Week 24;n=3	33.33 (0 to 86.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with JIA ACR Inactive Disease Status at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Percentage of Participants with JIA ACR Inactive Disease Status at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[103]
-----------------	---

End point description:

The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the scale used; duration of morning stiffness of ≤ 15 minutes. 95% CI was based on normal approximation. DBFAS was used. Missing response was imputed as non-response.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[103] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double- Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Percentage of Participants				
number (not applicable)				
DB Week 4	7.14	16.13		
DB Week 8	3.57	22.58		
DB Week 12	7.14	22.58		
DB Week 16	3.57	16.13		
DB Week 20	7.14	16.13		
DB Week 24	7.14	19.35		
DB Week 28	10.71	19.35		
DB Week 32	10.71	19.35		
DB Week 36	14.29	16.13		
DB Week 40	17.86	22.58		
DB Week 44	14.29	22.58		
DB Week 48	17.86	22.58		
DB Week 52	21.43	19.35		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
----------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[104]
Parameter estimate	Difference in percentage
Point estimate	-15.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.98
upper limit	2.1

Notes:

[104] - DB Week 12

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
----------------------------	---------------------------------------

Statistical analysis description:

DB Week 8

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[105]
Parameter estimate	Difference in percentage
Point estimate	-19.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.25
upper limit	-2.76

Notes:

[105] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[106]
Parameter estimate	Difference in percentage
Point estimate	-8.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.07
upper limit	7.1

Notes:

[106] - DB Week 4

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[107]
Parameter estimate	Difference in percentage
Point estimate	2.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.53
upper limit	22.68

Notes:

[107] - DB Week 52

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[108]
Parameter estimate	Difference in percentage
Point estimate	-8.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.66
upper limit	9.38

Notes:

[108] - DB Week 32

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[109]
Parameter estimate	Difference in percentage
Point estimate	-1.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.16
upper limit	16.48

Notes:

[109] - DB Week 36

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description: The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[110]
Parameter estimate	Difference in percentage
Point estimate	-4.72

Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.17
upper limit	15.72

Notes:

[110] - DB Week 40

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[111]
Parameter estimate	Difference in percentage
Point estimate	-8.29

Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.91
upper limit	11.32

Notes:

[111] - DB Week 44

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[112]
Parameter estimate	Difference in percentage
Point estimate	-4.72

Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.17
upper limit	15.72

Notes:

[112] - DB Week 48

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
-------------------	--

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[113]
Parameter estimate	Difference in percentage
Point estimate	-12.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.08
upper limit	4.65

Notes:

[113] - DB Week 24

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[114]
Parameter estimate	Difference in percentage
Point estimate	-8.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.07
upper limit	7.1

Notes:

[114] - DB Week 20

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[115]
Parameter estimate	Difference in percentage
Point estimate	-12.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.22
upper limit	2.1

Notes:

[115] - DB Week 16

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
-----------------------------------	---------------------------------------

Statistical analysis description:

The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	other ^[116]
Parameter estimate	Difference in percentage
Point estimate	-8.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.66
upper limit	9.38

Notes:

[116] - DB Week 28

Secondary: Percentage of Participants with JIA ACR Clinical Remission at DB Weeks 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

End point title	Percentage of Participants with JIA ACR Clinical Remission at DB Weeks 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase ^[117]
-----------------	--

End point description:

According to ACR, clinical remission was defined as clinical inactive disease for 24 weeks continuously while on medications. DBFAS was used. Missing response was imputed as non-response.

End point type	Secondary
----------------	-----------

End point timeframe:

DB Weeks 24, 28, 32, 36, 40, 44, 48, 52

Notes:

[117] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.

End point values	Tofacitinib 5mg BID Double-Blind (DB)	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	31		
Units: Percentage of participants				
number (not applicable)				
DB Week 24	0	3.23		
DB Week 28	0	3.23		
DB Week 32	0	3.23		
DB Week 36	3.57	3.23		
DB Week 40	3.57	3.23		
DB Week 44	3.57	6.45		
DB Week 48	3.57	9.68		
DB Week 52	3.57	9.68		

Statistical analyses

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 24	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-2.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.69
upper limit	5.76

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 32	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-2.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.69
upper limit	5.76

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 28	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-2.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.69
upper limit	5.76

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 48	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-6.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.58
upper limit	6.37

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 44	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-2.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.93
upper limit	8.17

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 40	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	0.35

Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.92
upper limit	9.62

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 52	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Method	Mixed Model for Repeated Measures
Parameter estimate	Difference in percentage
Point estimate	-6.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.58
upper limit	6.37

Statistical analysis title	Tofacitinib 5mg BID DB and Placebo DB
Statistical analysis description:	
DB Week 36	
Comparison groups	Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in LS Mean
Point estimate	0.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.92
upper limit	9.62

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From dose 1 up to 28 days after end of study treatment (maximum duration up to 16 weeks) for OL1 and for OL2 (maximum duration up to 24 weeks), For DB (maximum duration up to 248 weeks)

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	v26.1
--------------------	-------

Reporting groups

Reporting group title	Tofacitinib 5mg BID OL Part 1
-----------------------	-------------------------------

Reporting group description:

Participants were administered tofacitinib 5 mg BID via the oral route and continued to receive a stable dose of corticosteroids during open label part 1.

Reporting group title	Tofacitinib 5mg BID OL Part 2
-----------------------	-------------------------------

Reporting group description:

Participants who achieved sJIA American college of rheumatology (ACR) 50 response and maintained sJIA ACR 30 response for 4 weeks were administered tofacitinib 5 mg BID and tapering dose of CSs for participants treated with 0.2 mg/kg/day oral prednisone (or equivalent).

Reporting group title	Tofacitinib 5mg BID DB
-----------------------	------------------------

Reporting group description:

Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase continued to receive tofacitinib 5 mg BID orally during the double-blind withdrawal phase of the study.

Reporting group title	Placebo DB
-----------------------	------------

Reporting group description:

Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase were randomised to receive placebo BID orally during the double-blind withdrawal phase of the study.

Serious adverse events	Tofacitinib 5mg BID OL Part 1	Tofacitinib 5mg BID OL Part 2	Tofacitinib 5mg BID DB
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 100 (7.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Histiocytic necrotising lymphadenitis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease			

subjects affected / exposed	1 / 100 (1.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Overdose			
subjects affected / exposed	1 / 100 (1.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 100 (1.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Still's disease			
subjects affected / exposed	3 / 100 (3.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo DB		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 31 (6.45%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Histiocytic necrotising lymphadenitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hodgkin's disease			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Overdose			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue			

disorders			
Still's disease			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Tofacitinib 5mg BID OL Part 1	Tofacitinib 5mg BID OL Part 2	Tofacitinib 5mg BID DB
Total subjects affected by non-serious adverse events			
subjects affected / exposed	33 / 100 (33.00%)	15 / 54 (27.78%)	23 / 28 (82.14%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	6 / 100 (6.00%)	2 / 54 (3.70%)	4 / 28 (14.29%)
occurrences (all)	6	8	9
Feeling cold			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Condition aggravated			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	3 / 100 (3.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	3	0	1
Nasal obstruction			

subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	1 / 28 (3.57%) 1
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Restlessness subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	1 / 28 (3.57%) 1
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	1 / 28 (3.57%) 1
Blood urine present subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	1 / 28 (3.57%) 1
Eosinophil count increased subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	1 / 28 (3.57%) 1
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Hepatic enzyme increased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Red blood cell count increased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Monocyte count increased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Mean cell volume increased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Transaminases increased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
White blood cell count increased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
White blood cells urine positive			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Tibia fracture			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Skin laceration			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Skin abrasion			

subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Radius fracture			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Ligament sprain			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Contusion			
subjects affected / exposed	0 / 100 (0.00%)	2 / 54 (3.70%)	1 / 28 (3.57%)
occurrences (all)	0	2	1
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Febrile convulsion			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Eye disorders			

Refraction disorder subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Gastrointestinal disorders			
Vomiting subjects affected / exposed occurrences (all)	3 / 100 (3.00%) 3	0 / 54 (0.00%) 0	3 / 28 (10.71%) 6
Nausea subjects affected / exposed occurrences (all)	3 / 100 (3.00%) 4	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	1 / 28 (3.57%) 1
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	2 / 54 (3.70%) 2	0 / 28 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	1 / 28 (3.57%) 1
Gingival swelling subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Hepatobiliary disorders			
Hypertransaminasaemia subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	2 / 28 (7.14%) 2
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	3 / 100 (3.00%) 3	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Erythema nodosum subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	0 / 54 (0.00%) 0	0 / 28 (0.00%) 0
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Back pain			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Groin pain			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Still's disease			
subjects affected / exposed	0 / 100 (0.00%)	3 / 54 (5.56%)	8 / 28 (28.57%)
occurrences (all)	0	4	8
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	3 / 100 (3.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	3	0	0
Upper respiratory tract infection			
subjects affected / exposed	10 / 100 (10.00%)	7 / 54 (12.96%)	3 / 28 (10.71%)
occurrences (all)	11	11	11
Nasopharyngitis			

subjects affected / exposed	6 / 100 (6.00%)	0 / 54 (0.00%)	2 / 28 (7.14%)
occurrences (all)	8	0	2
Influenza			
subjects affected / exposed	3 / 100 (3.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	3	0	0
Acarodermatitis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Roseola			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Respiratory tract infection viral			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Pyoderma			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Pilonidal disease			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Pharyngotonsillitis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Pharyngitis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Mycoplasma infection			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Herpangina			

subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 100 (0.00%)	5 / 54 (9.26%)	0 / 28 (0.00%)
occurrences (all)	0	5	0
Bronchitis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Acute sinusitis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Tonsillitis bacterial			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Hypertriglyceridaemia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	3
Iron deficiency			
subjects affected / exposed	0 / 100 (0.00%)	0 / 54 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	2

Non-serious adverse events	Placebo DB		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 31 (80.65%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			

Pyrexia			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Feeling cold			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Condition aggravated			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nasal obstruction			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Upper-airway cough syndrome			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	2		
Oropharyngeal pain			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Restlessness			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		

Aspartate aminotransferase increased				
subjects affected / exposed	1 / 31 (3.23%)			
occurrences (all)	1			
Blood creatine phosphokinase increased				
subjects affected / exposed	1 / 31 (3.23%)			
occurrences (all)	1			
Blood urine present				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences (all)	0			
Eosinophil count increased				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences (all)	0			
Gamma-glutamyltransferase increased				
subjects affected / exposed	1 / 31 (3.23%)			
occurrences (all)	1			
Haemoglobin decreased				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences (all)	0			
Hepatic enzyme increased				
subjects affected / exposed	1 / 31 (3.23%)			
occurrences (all)	1			
Red blood cell count increased				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences (all)	0			
Monocyte count increased				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences (all)	0			
Mean cell volume increased				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences (all)	0			
Transaminases increased				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences (all)	0			
White blood cell count increased				

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
White blood cells urine positive			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Tibia fracture			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Skin laceration			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Skin abrasion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Radius fracture			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Limb injury			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Contusion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	10		
Febrile convulsion			

subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Neutropenia			
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 2		
Thrombocytosis			
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Eye disorders			
Refraction disorder			
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Nausea			
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Abdominal pain			
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Abdominal pain upper			
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Diarrhoea			
subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 3		
Gingival swelling			
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Toothache			

subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Hepatobiliary disorders Hypertransaminasaemia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all) Erythema nodosum subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1 1 / 31 (3.23%) 1		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all) Groin pain subjects affected / exposed occurrences (all) Joint range of motion decreased subjects affected / exposed occurrences (all) Joint swelling subjects affected / exposed occurrences (all) Musculoskeletal stiffness subjects affected / exposed occurrences (all) Myalgia subjects affected / exposed occurrences (all) Pain in extremity	1 / 31 (3.23%) 7 0 / 31 (0.00%) 0 1 / 31 (3.23%) 2 1 / 31 (3.23%) 1 1 / 31 (3.23%) 2 1 / 31 (3.23%) 1 2 / 31 (6.45%) 2		

subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	4		
Still's disease			
subjects affected / exposed	14 / 31 (45.16%)		
occurrences (all)	14		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	3		
Upper respiratory tract infection			
subjects affected / exposed	5 / 31 (16.13%)		
occurrences (all)	19		
Nasopharyngitis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Influenza			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Acarodermatitis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Roseola			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Respiratory tract infection viral			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	2		
Respiratory tract infection			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Pyoderma			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		

Pilonidal disease			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Pharyngotonsillitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Pharyngitis			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Mycoplasma infection			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Herpangina			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Gastroenteritis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
COVID-19			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Bronchitis			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Acute sinusitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Tonsillitis bacterial			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Hypertriglyceridaemia			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Iron deficiency			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 May 2019	Tofacitinib 10 mg BID dose will no longer be evaluated. References to the 10mg BID group and 10 mg BID dose increase at Day 14 are removed throughout the protocol.
17 March 2021	Participants who received previous JIA treatment with tofacitinib, baricitinib or any other JAK-inhibitor were excluded. This exclusion criterion was broadened to include any JAK-inhibitor.
21 July 2021	This global amendment incorporated updates to facilitate enrollment of sJIA participants who were previously treated with biological DMARDs or JAK-inhibitors.
09 February 2022	Discussion of the risks and benefits of using tofacitinib in the pediatric population added to the body of the protocol at the request of an ethics committee.
01 September 2023	This global amendment incorporated measures to further facilitate the interpretation of trial results. This included a modification to the statistical analysis. Additionally, editorial and typographic changes.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported